<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Zhao Ni | Swcyo</title>
    <link>https://swcyo.netlify.app/author/zhao-ni/</link>
      <atom:link href="https://swcyo.netlify.app/author/zhao-ni/index.xml" rel="self" type="application/rss+xml" />
    <description>Zhao Ni</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><copyright>© {2021} Song Ou-Yang</copyright><lastBuildDate>Wed, 01 Jul 2020 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://swcyo.netlify.app/media/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_512x512_fill_lanczos_center_3.png</url>
      <title>Zhao Ni</title>
      <link>https://swcyo.netlify.app/author/zhao-ni/</link>
    </image>
    
    <item>
      <title>Downregulation of ST3GAL5 is associated with muscle invasion, high grade and a poor prognosis in patients with bladder cancer</title>
      <link>https://swcyo.netlify.app/publication/journal-article/</link>
      <pubDate>Wed, 01 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://swcyo.netlify.app/publication/journal-article/</guid>
      <description>&lt;p&gt;Keywords: ST3 β-galactoside α-2,3-sialyltransferase 5; bladder cancer; high grade; methylation; muscle invasive; prognosis.&lt;/p&gt;
&lt;h2 id=&#34;introduction&#34;&gt;Introduction&lt;/h2&gt;
&lt;p&gt;Bladder cancer (BC) is the 7th most common cancer affecting men in the world and the 11th most common cancer in the total population (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b1-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;1&lt;/a&gt;). BC affects ~3.4 million people worldwide, with 430,000 new cases diagnosed in 2015 (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b2-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;2&lt;/a&gt;). In the United States, 80,470 new cases of BC and 17,670 BC-associated mortality cases were expected to occur in 2019 (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b3-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;3&lt;/a&gt;). Furthermore, BC incidence and mortality rates vary across countries due to the differences in risk factors, detection and diagnostic practices and treatments availability (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b4-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;4&lt;/a&gt;). The most common type of BC is bladder urothelial carcinoma (BLCA), which accounts for ~90% of all cases (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b5-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;5&lt;/a&gt;). In addition, BLCA can be low grade or high grade (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b6-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;6&lt;/a&gt;). Low grade BLCA rarely results in cancer invasion in the bladder muscular wall or metastasis to other parts of the body, and patients rarely succumb to low grade BLCA; however, the majority of BLCA-associated mortality cases result from the high-grade disease (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b6-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;6&lt;/a&gt;). BC can also be stratified into muscle invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC), according to invasion of the muscularis propria (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b6-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;6&lt;/a&gt;). In particular, ~75% of newly diagnosed BC cases are non-invasive, including Stages Ta, Tis or T1, based according to the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system (8th edition) (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b4-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;4&lt;/a&gt;). NMIBC exhibits a high prevalence due to the long-term survival rates and the lower risk of cancer-specific mortality compared with patients with MIBC (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b6-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;6&lt;/a&gt;). Furthermore, improvements in the early detection and treatment of BC have increased patient survival status; however, BC-associated mortality remains high. It is therefore crucial to identify novel biomarkers and potential therapeutic targets to improve the clinical treatment of patients with BLCA.&lt;/p&gt;
&lt;p&gt;ST3 β-galactoside α-2,3-sialyltransferase 5 (ST3GAL5) is a protein coding gene, which catalyzes the formation of ganglioside monosialodihexosylganglioside (GM3) (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b7-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;7&lt;/a&gt;). Ganglioside GM3 is known to participate in the induction of cell differentiation, modulation of cell proliferation, maintenance of fibroblast morphology, signal transduction and integrin-mediated cell adhesion (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b8-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;8&lt;/a&gt;). Furthermore, ganglioside GM3 is associated with numerous types of tumor, including lung cancer, brain cancer and melanomas, and was reported to significantly influence cancer development and progression (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b9-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;9&lt;/a&gt;–&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b12-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;12&lt;/a&gt;). GM3 is also upregulated in several types of cancer, such as lung and brain cancer, and melanoma, and can be used as a tumor-associated carbohydrate antigen in immunotherapy (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b9-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;9&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b10-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;10&lt;/a&gt;). In addition, GM3 inhibits tumor cell proliferation through angiogenesis inhibition or decrease in cell motility (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b9-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;9&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b11-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;11&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b13-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;13&lt;/a&gt;). However, the expression profile and functional role of ST3GAL5 in BLCA remain unclear. Therefore, to the best of our knowledge, the present study is the first data mining study to predict the potential role of ST3GAL5 in BLCA, based on publicly available gene expression and clinical outcome databases.&lt;/p&gt;
&lt;p&gt;In the present study, the expression of ST3GAL5 and its clinical outcomes were investigated in patients with BLCA using various public gene expression and survival datasets. In addition, the DNA methylation and gene expression patterns of ST3GAL5 in BLCA were analyzed. Furthermore, enrichment analyses were performed on genes that were positively co-expressed with ST3GAL5 in BLCA, and gene set enrichment analysis (GSEA) was also used. The findings from the present study hypothesized that ST3GAL5 downregulation may influence BLCA carcinogenesis, suggesting that ST3GAL5 may represent a novel therapeutic target in BLCA.&lt;/p&gt;
&lt;h2 id=&#34;materials-and-methods&#34;&gt;Materials and methods&lt;/h2&gt;
&lt;h4 id=&#34;data-set-acquisition-and-processing&#34;&gt;Data set acquisition and processing&lt;/h4&gt;
&lt;p&gt;All data were acquired and processed from the public bioinformatics databases Gene Expression Omnibus (GEO; &lt;a href=&#34;http://www.ncbi.nlm.nih.gov/geo&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;www.ncbi.nlm.nih.gov/geo&lt;/a&gt;) (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b14-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;14&lt;/a&gt;), Oncomine (&lt;a href=&#34;http://www.oncomine.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;www.oncomine.org&lt;/a&gt;) (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b15-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;15&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b16-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;16&lt;/a&gt;), Tumor IMmune Estimation Resource (TIMER; cistrome.shinyapps.io/timer) (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b17-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;17&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b18-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;18&lt;/a&gt;), Gene Expression across Normal and Tumor tissue (GENT; medical-genome.kribb.re.kr/GENT) (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b19-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;19&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b20-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;20&lt;/a&gt;), University of California, Santa Cruz (UCSC) Xena (xenabrowser.net) (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b21-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;21&lt;/a&gt;), Gene expression Profiling Interactive Analysis 2 (GEPIA2; gepia2.cancer-pku.cn) (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b22-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;22&lt;/a&gt;) and Kaplan-Meier plotter (&lt;a href=&#34;http://kmplot.com/analysis&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;kmplot.com/analysis&lt;/a&gt;) (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b23-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;23&lt;/a&gt;). The BLCA microarray datasets &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13507&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE13507&lt;/a&gt; (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b24-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;24&lt;/a&gt;), &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120736&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE120736&lt;/a&gt; (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b25-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;25&lt;/a&gt;) and &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31684&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE31684&lt;/a&gt; (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b25-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;25&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b26-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;26&lt;/a&gt;) were downloaded from the GEO database to analyze the expression of ST3GAL5. The Lee Bladder (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b27-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;27&lt;/a&gt;), Blaveri Bladder 2 (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b28-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;28&lt;/a&gt;), Sanchez-Carbayo Bladder 2 (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b29-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;29&lt;/a&gt;) and Stransky Bladder (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b30-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;30&lt;/a&gt;) datasets from the Oncomine database were extracted and processed using the R package ‘ROncomine’ v0.0.0.9 (&lt;a href=&#34;http://github.com/yikeshu0611/ROncomine&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;github.com/yikeshu0611/ROncomine&lt;/a&gt;). The datasets from Genomic Data Commons (GDC; &lt;a href=&#34;http://gdc.cancer.gov/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;gdc.cancer.gov&lt;/a&gt;), The Cancer Genome Atlas (TCGA; &lt;a href=&#34;http://cancergenome.nih.gov/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;cancergenome.nih.gov&lt;/a&gt;) and Genotype-Tissue Expression (GTEx; &lt;a href=&#34;http://commonfund.nih.gov/GTEx&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;commonfund.nih.gov/GTEx&lt;/a&gt;) databases were downloaded using UCSC Xena browser tool (&lt;a href=&#34;http://xenabrowser.net/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;xenabrowser.net/&lt;/a&gt;). In the Oncomine database, the default settings were used and the threshold parameters were as follows: P&amp;lt;1×10−4, |fold change|&amp;gt;2 and gene rank in the top 10%. In the GENT database, data were analyzed using the Human Genome U133 Plus 2.0 Array platform (&lt;a href=&#34;http://www.affymetrix.com/support/technical/byproduct.affx?product=hg-u133-plus&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;http://www.affymetrix.com/support/technical/byproduct.affx?product=hg-u133-plus&lt;/a&gt;).&lt;/p&gt;
&lt;h4 id=&#34;enrichment-analysis&#34;&gt;Enrichment analysis&lt;/h4&gt;
&lt;p&gt;The Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were determined using the R package ‘clusterProfiler’ v3.14.3 (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b31-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;31&lt;/a&gt;), and the Reactome pathway enrichment analysis was performed using the R package ‘ReactomePA’ v1.30.0 (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b32-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;32&lt;/a&gt;). Subsequently, the gene-concept network analysis were performed using the R package ‘clusterProfiler’ and ‘ReactomePA’. Microarray datasets of accession number &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83586&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE83586&lt;/a&gt; (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b33-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;33&lt;/a&gt;) were downloaded from the GEO database in order to investigate the relevant signaling pathways using GSEA. According to the mean expression value of ST3GAL5 in the &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83586&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE83586&lt;/a&gt; dataset, the matrix file was divided into high- and low-expression groups, and GSEA was performed using GSEA 4.02 software (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b34-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;34&lt;/a&gt;) in order to determine the KEGG pathways (c2.cp.kegg.v7.0.symbols) associated with high and low expression of ST3GAL5. Gene set permutations were performed 1,000 times for each analysis. The false discovery rate &amp;lt;0.25, |normalized enrichment score| &amp;gt;1 and nominal P&amp;lt;0.05 were considered to indicate a statistically significant difference. Subsequently, replotting of the output from the GSEA report folder was conducted using the R package ‘Rtoolbox’ v1.4 (&lt;a href=&#34;http://github.com/PeeperLab/Rtoolbox&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;github.com/PeeperLab/Rtoolbox&lt;/a&gt;).&lt;/p&gt;
&lt;h4 id=&#34;data-management-and-statistical-analysis&#34;&gt;Data management and statistical analysis&lt;/h4&gt;
&lt;p&gt;Cancer staging was assessed using the 8th edition of the UICC/AJCC cancer staging system. The gene expression profile and survival data were downloaded, converted, constructed and managed using Microsoft Office Excel 2016 (Microsoft Corporation). All statistical analyses were performed using R software (&lt;a href=&#34;http://www.r-project.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;www.r-project.org&lt;/a&gt;; v3.6.1). The box plot was constructed using the R package ‘ggplot2’ v3.2.1 (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b35-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;35&lt;/a&gt;). The Cnetplot was constructed using the R package ‘clusterProfiler’ and ‘ReactomePA’. Student&amp;rsquo;s t-test was used to compare the means of two independent samples, and one-way ANOVA was used to compare the means of multiple independent samples followed by Bonferroni post hoc test for multiple comparisons. Kaplan-Meier analysis and Cox proportional hazard models were used for survival analysis by using R package ‘survival’ v3.1.8 and ‘survminer’ v0.4.6. A multivariate Cox proportional hazards regression model was performed to adjust for covariate effects, and stratification analysis was used to reduce the potential confounding effect on the estimation of hazard ratio (HR). Missing data were coded and excluded from the analysis. P&amp;lt;0.05 was considered to indicate a statistically significant difference.&lt;/p&gt;
&lt;h2 id=&#34;results&#34;&gt;Results&lt;/h2&gt;
&lt;h4 id=&#34;expression-of-st3gal5-in-different-types-of-cancer&#34;&gt;Expression of ST3GAL5 in different types of cancer&lt;/h4&gt;
&lt;p&gt;The differences in ST3GAL5 expression between various types of cancer and paired healthy tissues were compared from three independent bioinformatics databases. In the Oncomine database, the comparison between each type of cancer and healthy tissues identified the downregulation of ST3GAL5 expression in bladder, lung, ovarian, prostate and ‘other’ cancers, and the upregulation of ST3GAL5 expression in esophageal cancer, head and neck cancer, kidney cancer, leukemia, lymphoma, melanoma and myeloma (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f1-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 1A&lt;/a&gt;). ST3GAL5 expression was also analyzed in tumor and healthy tissues using TCGA data and the TIMER tool (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f1-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 1B&lt;/a&gt;). Among the different types of cancer, 10 presented significantly lower ST3GAL5 expression, and five had significantly higher ST3GAL5 expression compared with paired healthy tissues (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f1-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 1B&lt;/a&gt;). Furthermore, data from the GENT database indicated that ST3GAL5 expression was downregulated in certain cancer types, including bladder, blood, brain, breast, liver, ovary, prostate, stomach and testicular cancers (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f1-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 1C&lt;/a&gt;). The three databases demonstrated the downregulation of ST3GAL5 in different cancer types. Furthermore, ST3GAL5 expression in BLCA tissues was significantly decreased in the three databases compared with paired healthy tissues.&lt;/p&gt;
&lt;p&gt;















&lt;figure  id=&#34;figure-click-on-image-to-zoom&#34;&gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img src=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/bin/ol-20-01-0828-g00.jpg&#34; alt=&#34;An external file that holds a picture, illustration, etc.
Object name is ol-20-01-0828-g00.jpg&#34; loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;figcaption&gt;
      Click on image to zoom
    &lt;/figcaption&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f1-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Figure 1.&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Expression of ST3GAL5 in different types of cancer. (A) Expression of ST3GAL5 in 20 types of cancer vs. healthy tissues from the Oncomine database. The cell color is determined by the best gene rank percentile for the analysis within the cell. Red color represents overexpression and blue color represents downregulation. (B) Expression of ST3GAL5 in different types of tumor vs. healthy tissues in data from the Tumor IMmune Estimation Resource website. Boxes represent the median, 25 and 75th percentiles, and each dot represents expression of samples. (C) Expression of ST3GAL5 in tumor vs. healthy tissues from the Gene Expression across Normal and Tumor tissue database. Boxes represent the median, 25 and 75th percentiles, and dots represent outliers. ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5.&lt;/p&gt;
&lt;h4 id=&#34;expression-of-st3gal5-in-blca-and-healthy-bladder-tissues&#34;&gt;Expression of ST3GAL5 in BLCA and healthy bladder tissues&lt;/h4&gt;
&lt;p&gt;To observe the expression of ST3GAL5 in BLCA, three independent datasets from TGCA + GTEx, Oncomine and GEO databases were analyzed. Data from TCGA + GTEx database were acquired using the USCS Xena browser tool. Moreover, data from the Oncomine Lee Bladder dataset were extracted and processed using the R package ‘ROncomine’. The GEO datasets were acquired from the accession number &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13507&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE13507&lt;/a&gt;. The results demonstrated a significant downregulation of ST3GAL5 in BLCA tissues compared with healthy bladder tissues (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f2-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 2A-C&lt;/a&gt;).&lt;/p&gt;
&lt;p&gt;















&lt;figure  id=&#34;figure-click-on-image-to-zoom&#34;&gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img src=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/bin/ol-20-01-0828-g01.jpg&#34; alt=&#34;An external file that holds a picture, illustration, etc.
Object name is ol-20-01-0828-g01.jpg&#34; loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;figcaption&gt;
      Click on image to zoom
    &lt;/figcaption&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f2-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Figure 2.&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Expression of ST3GAL5 between BLCA and healthy bladder tissues. (A) Expression of ST3GAL5 in BLCA from TCGA + GTEx databases, the data was downloaded from UCSC Xena browser tool. (B) Expression of ST3GAL5 in BLCA from the Oncomine database, the threshold was designed using default settings parameters: P&amp;lt;1×10−4, |fold-change|&amp;gt;2, and gene rank in top 10%. (C) The expressions of ST3GAL5 in BLCA from the GEO database under accession numbers &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13507&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE13507&lt;/a&gt;. TCGA, The Cancer Genome Atlas; GTEx, Genotype-Tissue Expression; UCSC, University of California, Santa Cruz; BLCA, bladder urothelial carcinoma; ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5.&lt;/p&gt;
&lt;h4 id=&#34;expression-of-st3gal5-in-mibc-and-high-grade-blca-tissues&#34;&gt;Expression of ST3GAL5 in MIBC and high-grade BLCA tissues&lt;/h4&gt;
&lt;p&gt;To further determine of ST3GAL5 expression in MIBC and high-grade BLCA, four individual datasets from the Oncomine database were analyzed (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/table/tI-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Table I&lt;/a&gt;). The results from meta-analysis demonstrated that ST3GAL5 was significantly downregulated in MIBC across the four datasets (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/table/tI-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Table I&lt;/a&gt;). In these four datasets, ST3GAL5 was significantly downregulated in MIBC and high-grade BLCA (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f3-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 3A-a1-4 and B-a1-4&lt;/a&gt;). The data acquired from the GEO datasets &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120736&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE120736&lt;/a&gt;, &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31684&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE31684&lt;/a&gt; and &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13507&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE13507&lt;/a&gt; also presented significantly lower expression of ST3GAL5 in MIBC and high-grade BLCA (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f3-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 3A-b1-3 and B-b1-3&lt;/a&gt;, respectively). In addition, decreased expression of ST3GAL5 in high-grade BLCA tissues was reported in the GDC + TCGA BLCA datasets, using the USCS Xena browser tool (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f3-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 3C&lt;/a&gt;). Taken together, these results demonstrated that ST3GAL5 downregulation was associated with MIBC and high-grade BLCA.&lt;/p&gt;
&lt;p&gt;















&lt;figure  id=&#34;figure-click-on-image-to-zoom&#34;&gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img src=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/bin/ol-20-01-0828-g02.jpg&#34; alt=&#34;An external file that holds a picture, illustration, etc.
Object name is ol-20-01-0828-g02.jpg&#34; loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;figcaption&gt;
      Click on image to zoom
    &lt;/figcaption&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f3-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Figure 3.&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Expression of ST3GAL5 in MIBC and high-grade BLCA. (A) Expression of ST3GAL5 in MIBC compared with NMIBC. (A-a-1) Stansky Bladder dataset from the Oncomine database reported lower expression of ST3GAL5 in MIBC. (A-a-2) Lee Bladder dataset from the Oncomine database reported lower expression of ST3GAL5 in MIBC. (A-a-3) Blaveri Bladder 2 dataset from the Oncomine database reported lower expression of ST3GAL5 in MIBC. (A-a-4) Sanchez-Carbayo Bladder 2 dataset from the Oncomine database reported lower expression of ST3GAL5 in MIBC. (A-b-1) &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120736&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE120736&lt;/a&gt; dataset from the GEO database presented lower expression of ST3GAL5 in MIBC. (A-b-2) &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31684&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE31684&lt;/a&gt; dataset from the GEO database presented lower expression of ST3GAL5 in MIBC. (A-b-3) &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13507&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE13507&lt;/a&gt; dataset from the GEO database presented lower expression of ST3GAL5 in MIBC. (B) Expression of ST3GAL5 in high grade BLCA compared with low grade BLCA. (B-a-1) Stansky Bladder dataset from the Oncomine database demonstrated lower expression of ST3GAL5 in high grade BLCA. (B-a-2) Lee Bladder dataset from the Oncomine database demonstrated lower expression of ST3GAL5 in high grade BLCA. (B-a-3) Blaveri Bladder 2 dataset from the Oncomine database demonstrated lower expression of ST3GAL5 in high grade BLCA. (B-a-4) Sanchez-Carbayo Bladder 2 from the Oncomine database demonstrated lower expression of ST3GAL5 in high grade BLCA. (B-b-1) &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120736&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE120736&lt;/a&gt; dataset from the GEO database presented lower expression of ST3GAL5 in high grade BLCA. (B-b-2) &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31684&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE31684&lt;/a&gt; from the GEO database presented lower expression of ST3GAL5 in high grade BLCA. (B-b-3) &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13507&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE13507&lt;/a&gt; from the GEO database presented lower expression of ST3GAL5 in high grade BLCA. (C) GDC + TCGA-BLCA dataset showed lower expression of ST3GAL5 in high grade BLCA. TCGA, The Cancer Genome Atlas; BLCA, bladder urothelial carcinoma; ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5; MIBC, muscle invasive bladder cancer; NMIBC, non-muscle invasive bladder cancer; GEO, Gene Expression Omnibus; GDC, Genomic Data Commons.&lt;/p&gt;
&lt;h3 id=&#34;table-i&#34;&gt;Table I.&lt;/h3&gt;
&lt;p&gt;Comparison of ST3 β-galactoside α-2,3-sialyltransferase 5 across four datasets in the downregulation analysis from the Oncomine database.&lt;/p&gt;
&lt;table&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:left&#34;&gt;Dataset&lt;/th&gt;
&lt;th style=&#34;text-align:center&#34;&gt;FC&lt;/th&gt;
&lt;th style=&#34;text-align:center&#34;&gt;P-value&lt;/th&gt;
&lt;th style=&#34;text-align:center&#34;&gt;Gene rank&lt;/th&gt;
&lt;th style=&#34;text-align:center&#34;&gt;MIBC&lt;/th&gt;
&lt;th style=&#34;text-align:center&#34;&gt;NMIBC&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;Sanchez-Carbayo Bladder 2&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;−9.324&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;2.43×10−9&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;315 (in top 3%)&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;32&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;25&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;Blaveri Bladder 2&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;−3.622&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;2.86×10−9&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;66 (in top 2%)&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;62&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;126&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;Stransky Bladder&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;−5.276&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;3.02×10−10&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;3 (in top 1%)&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;22&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;19&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;Lee Bladder&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;2.627&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;2.43×10−12&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;7 (in top 1%)&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;81&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;28&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;Meta-analysis: Median Rank=36.5, P=2.64×10−9. FC, fold-change; MIBC, muscle invasive bladder cancer; NMIBC, non-muscle invasive bladder cancer.&lt;/p&gt;
&lt;h4 id=&#34;association-between-st3gal5-expression-and-clinicopathological-characteristics-of-patients-with-blca&#34;&gt;Association between ST3GAL5 expression and clinicopathological characteristics of patients with BLCA&lt;/h4&gt;
&lt;p&gt;The present study investigated the association between ST3GAL5 mRNA expression, promoter methylation level and the clinicopathological characteristics of patients with BLCA from the TCGA-BLCA dataset by using the Xena web tool. Compared with healthy bladder tissues, the expression of ST3GAL5 was downregulated in tissues from primary tumors, Stage IV cancer, extreme weight, smoking for &amp;gt;15 years, non-papillary tumors and nodal metastasis status N1 (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/table/tII-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Table II&lt;/a&gt;). Furthermore, ST3GAL5 expression was downregulated in male and female patients with BLCA. However, the level of ST3GAL5 promoter methylation in patients with BLCA was significantly decreased, regardless of patient clinicopathological characteristics, including cancer stage, ethnicity, sex, age, weight, smoking status, nodal metastasis status and histological subtype compared with healthy patients (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f4-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 4&lt;/a&gt;). Therefore, it was hypothesized that decreased ST3GAL5 promoter methylation may be positively associated with numerous clinicopathological characteristics of patients with BLCA.&lt;/p&gt;
&lt;p&gt;















&lt;figure  id=&#34;figure-click-on-image-to-zoom&#34;&gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img src=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/bin/ol-20-01-0828-g03.jpg&#34; alt=&#34;An external file that holds a picture, illustration, etc.
Object name is ol-20-01-0828-g03.jpg&#34; loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;figcaption&gt;
      Click on image to zoom
    &lt;/figcaption&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f4-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Figure 4.&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Box plots from TCGA clinical data according to categorization of the clinicopathological characteristics of patients with BLCA and healthy patients (normal). Promoter methylation of ST3GAL5 in BLCA (different color plot) and healthy (red plot) tissues based on (A) sample type, (B) individual cancer stages, (C) ethnicity, (D) sex, (E) age, (F) weight, (G) smoking status, (H) nodal metastasis status and (I) histological subtype. The β-value for assessment of methylation level ranged from 0 (least methylated) to 1 (most methylated). NW, normal weight; EW, extreme weight; EO, extreme obese; RS1, reformed smoker (&amp;lt;15 years); RS2, reformed smoker (&amp;gt;15 years); TCGA, The Cancer Genome Atlas; BLCA, bladder urothelial carcinoma; ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5; Yrs, years; N1, metastases in 1–3 axillary lymph nodes; N2, metastases in 4–9 axillary lymph nodes; N3, metastases in ≥10 axillary lymph nodes.&lt;/p&gt;
&lt;h3 id=&#34;table-ii&#34;&gt;Table II.&lt;/h3&gt;
&lt;p&gt;Association between ST3 β-galactoside α-2,3-sialyltransferase 5 expression and clinicopathological characteristics of patients with bladder urothelial carcinoma.&lt;/p&gt;
&lt;p&gt;In multiple comparisons, the healthy group represented the reference group. Patients with body mass index (BMI) 18–24 were classified as ‘Normal weight’, those with BMI 25–29 were classified as ‘Extreme weight’, those with BMI 30–39 were classified as ‘Obese’ and those with BMI ≥40 as ‘Extreme obese’. Data regarding weight, smoking habits, nodal metastasis status and histological subtype were missing (NA) for some patients with primary tumor. N0, No regional lymph node metastasis; N1, Metastases in 1–3 axillary lymph nodes; N2, Metastases in 4–9 axillary lymph nodes; N3, Metastases in ≥10 axillary lymph nodes; NA, not available.&lt;/p&gt;
&lt;h4 id=&#34;association-between-st3gal5-expression-and-survival-prognosis-in-patients-with-blca&#34;&gt;Association between ST3GAL5 expression and survival prognosis in patients with BLCA&lt;/h4&gt;
&lt;p&gt;To investigate the association between ST3GAL5 expression and survival prognosis in patients with BLCA, Kaplan-Meier survival analysis was performed using data from the GDC, TCGA and GEO databases via the UCSC Xena browser and Kaplan-Meier plotter web tools. The 5-year overall survival (OS), disease specific survival, progression free interval and relapse free survival were all positively associated with lower ST3GAL5 expression in patients with BLCA (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f5-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 5A-E&lt;/a&gt;).&lt;/p&gt;
&lt;p&gt;















&lt;figure  id=&#34;figure-click-on-image-to-zoom&#34;&gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img src=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/bin/ol-20-01-0828-g04.jpg&#34; alt=&#34;An external file that holds a picture, illustration, etc.
Object name is ol-20-01-0828-g04.jpg&#34; loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;figcaption&gt;
      Click on image to zoom
    &lt;/figcaption&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f5-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Figure 5.&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Assessment of the 5-year overall survival according to ST3GAL5 expression in patients with BLCA. Survival plot data from the UCSC Xena browse tool, gene expression data and (A) overall survival, (B) disease specific survival and (C) progression free interval information were downloaded from TCGA-BLCA datasets. Survival plots from the KM plotter, gene expression data and (D) overall survival and (E) relapse free survival information were downloaded from the GEO, EGA and TCGA datasets. Analyses focused on ST3GAL5 expression in patients with BLCA. (F) Forest plots of the GEO datasets evaluating association of ST3GAL5 with the overall survival in patients with BLCA using GENT2 web tool. TCGA, The Cancer Genome Atlas; BLCA, bladder urothelial carcinoma; ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5; GEO, Gene Expression Omnibus; EGA, European Genome-phenome Archive; GENT, Gene Expression across Normal and Tumor tissue; UCSC, University of California, Santa Cruz; HR, hazard ratio.&lt;/p&gt;
&lt;p&gt;Meta-survival analysis of OS was performed using data from GENT2 web (gent2.appex.kr/gent2) tools and depicted as forest plots (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f5-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 5F&lt;/a&gt;). The results demonstrated that low ST3GAL5 expression was associated with poor OS [P&amp;lt;0.001; HR, 2.934; 95% CI (1.916–4.493); &lt;em&gt;τ&lt;/em&gt;2, 0.086; I2, 0.884]. These results indicated the prognostic relevance of ST3GAL5 expression in patients with BLCA.&lt;/p&gt;
&lt;h4 id=&#34;enrichment-analysis-genes-co-expressed-with-st3gal5-in-blca-samples&#34;&gt;Enrichment analysis genes co-expressed with ST3GAL5 in BLCA samples&lt;/h4&gt;
&lt;p&gt;The top 250 genes that were positively co-expressed with ST3GAL5 in BLCA samples were identified using Oncomine Stransky Bladder dataset and GEPIA2 and UALCAN web tools. The genes common to these three databases were selected for further analysis. In total, 33 genes were identified as positively co-expressed with ST3GAL5 in BLCA samples. The names of the genes were as follows: [methyltransferase like 7A, SMAD6, ATPase phospholipid transporting 8B1, sortilin related receptor 1, trafficking kinesin protein 1, pterin-4 α-carbinolamine dehydratase 1, cytochrome b5 type A, isocitrate dehydrogenase (NADP(+)) 1, fructose-bisphosphatase 1, GATA binding protein 3, cathepsin H, dual specificity phosphatase 2, TP53 target 1, inhibitor of DNA binding (ID) 1, phospholipase C eta 2, solute carrier family (SLC) 14 member 1 (Kidd blood group), arachidonate 5-lipoxygenase, PPFIA binding protein 2, transmembrane protein 63A, 4-aminobutyrate aminotransferase, intraflagellar transport 140, SLC23A2, zinc finger protein 211, keratin associated protein 5–9, oviductal glycoprotein 1, family with sequence similarity 13 member A, ID2, carbonyl reductase 4, glycerol-3-phosphate dehydrogenase 1 like, carnitine O-octanoyltransferase, tubulin tyrosine ligase like 3, aldehyde dehydrogenase 4 family member A1 and malic enzyme 3].&lt;/p&gt;
&lt;p&gt;Subsequently, GO, KEGG and Reactome pathway enrichment analyses, and gene-concept network analysis were performed with ST3GAL5 and the 33 positively co-expressed genes by using the R packages ‘clusterProfiler’ and ‘ReactomePA’. GO terms functional enrichment analysis was performed with ST3GAL5 and its associated genes to determine the functions associated with biological processes (BP), molecular functions (MF) and cellular components (CC). ST3GAL5 and its co-expressed genes were predominantly associated with ‘coenzyme metabolic process’, ‘organic hydroxy compound metabolic process’, ‘negative regulation of osteoblast differentiation’, ‘renal system development’, ‘tertiary granule lumen’, ‘tertiary granule’, ‘ficolin-1-rich granule lumen’, ‘coenzyme binding’, ‘NAD binding’ and ‘cofactor binding’ (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f6-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 6A and B&lt;/a&gt;).&lt;/p&gt;
&lt;p&gt;















&lt;figure  id=&#34;figure-click-on-image-to-zoom&#34;&gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img src=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/bin/ol-20-01-0828-g05.jpg&#34; alt=&#34;An external file that holds a picture, illustration, etc.
Object name is ol-20-01-0828-g05.jpg&#34; loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;figcaption&gt;
      Click on image to zoom
    &lt;/figcaption&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f6-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Figure 6.&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Enrichment analysis of genes co-expressed with ST3GAL5 in BLCA samples. Bar plot showing the GO terms and signaling pathways of ST3GAL5 and its positively co-expressed genes in BLCA (left column). Cnetplot showing the links between genes and biological processes by using GO, KEGG pathways or Reactome pathways as networks (right column). (A) Bar plots of GO terms enrichment. (B) Cnetplot of GO terms. (C) Bar plots of KEGG pathways. (D) Cnetplot of KEGG pathways. (E) Bar plot of Reactome pathways. (F) Cnetplot of Reactome pathways. Length of the bar represents the gene count; the color represents the P-value or adjusted P-value. P Cutoff=0.05, Q Cutoff=0.2, P adjusted method=BH. BLCA, bladder urothelial carcinoma; ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BH, Benjamini-Hochberg.&lt;/p&gt;
&lt;p&gt;Furthermore, the KEGG pathways analysis for ST3GAL5 and its co-expressed genes demonstrated their association with ‘transforming growth factor (TGF)-β signaling pathway’, ‘carbon metabolism’, ‘alanine, aspartate and glutamate metabolism’, ‘peroxisome’, ‘glycosphingolipid biosynthesis-ganglio series’, ‘fatty acid biosynthesis’, ‘2-oxocarboxylic acid metabolism’ and ‘signaling pathways regulating pluripotency of stem cells’ (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f6-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 6C and D&lt;/a&gt;).&lt;/p&gt;
&lt;p&gt;Next, Reactome pathway analysis of ST3GAL5 and its co-expressed genes identified highlighted their association with ‘protein localization’, ‘neutrophil degranulation’, ‘peroxisomal protein import’, ‘fatty acid metabolism’, ‘metabolism of vitamins and cofactors’, ‘interaction with cumulus cells and the zona pellucida’, ‘phenylalanine and tyrosine metabolism’ and ‘interleukin (IL)-4 and IL-13 signaling’ (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f6-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 6E and F&lt;/a&gt;). All these pathways may therefore be associated with BLCA tumor progression and tumorigenesis.&lt;/p&gt;
&lt;h4 id=&#34;gsea-analysis-between-high-and-low-st3gal5-expression-in-blca&#34;&gt;GSEA analysis between high and low ST3GAL5 expression in BLCA&lt;/h4&gt;
&lt;p&gt;To further identify the signaling pathways that are differentially activated in BLCA, GSEA was performed to investigate the difference between high- (n=124) and low-ST3GAL5 (n=183) expression groups by using the GEO dataset &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83586&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;GSE83586&lt;/a&gt;. Three tumor-associated pathways were identified as significantly associated with the downregulation of ST3GAL5 expression in BLCA tissues, including ‘NOD-like receptor (NLR) signaling pathway’, ‘cytokine-cytokine receptor interaction’ and ‘Janus kinase (JAK)-STAT signaling pathway’ (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/table/tIII-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Table III&lt;/a&gt;; &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f7-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Fig. 7&lt;/a&gt;).&lt;/p&gt;
&lt;p&gt;















&lt;figure  id=&#34;figure-click-on-image-to-zoom&#34;&gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img src=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/bin/ol-20-01-0828-g06.jpg&#34; alt=&#34;An external file that holds a picture, illustration, etc.
Object name is ol-20-01-0828-g06.jpg&#34; loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;figcaption&gt;
      Click on image to zoom
    &lt;/figcaption&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/figure/f7-ol-0-0-11597/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Figure 7.&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;GSEA analysis between high and low expression of ST3GAL5 in BLCA. In total, three tumor-related signaling pathways were identified as positively associated with ST3GAL5 downregulation in BLCA. (A) NOD-like receptor signaling pathway. (B) Cytokine-cytokine receptor interaction. (C) JAK-STAT signaling pathway. JAK, Janus kinase; BLCA, bladder urothelial carcinoma; ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5; ES, enrichment score; NES, normalized enrichment score; NOM, nominal; FDR, false discovery rate.&lt;/p&gt;
&lt;h3 id=&#34;table-iii&#34;&gt;Table III.&lt;/h3&gt;
&lt;p&gt;Gene set enrichment analysis in the group with low expression levels of ST3 β-galactoside α-2,3-sialyltransferase 5 in bladder urothelial carcinoma.&lt;/p&gt;
&lt;table&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:left&#34;&gt;Gene set name&lt;/th&gt;
&lt;th style=&#34;text-align:center&#34;&gt;NES&lt;/th&gt;
&lt;th style=&#34;text-align:center&#34;&gt;NOM P-value&lt;/th&gt;
&lt;th style=&#34;text-align:center&#34;&gt;FDR&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;1.788003&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.00396&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.212486&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;KEGG_AUTOIMMUNE_THYROID_DISEASE&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;1.596979&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.027237&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.242572&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;1.593668&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.028689&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.212411&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;KEGG_ALLOGRAFT_REJECTION&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;1.579419&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.044747&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.208527&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDROITIN_SULFATE&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;1.577063&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.026923&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.189083&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;1.534106&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.035644&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.198596&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;1.502448&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.042969&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.213385&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;KEGG_JAK_STAT_SIGNALING_PATHWAY&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;1.500872&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.042718&lt;/td&gt;
&lt;td style=&#34;text-align:center&#34;&gt;0.201288&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;Gene sets with |NES|&amp;gt;1, NOM P&amp;lt;0.05 and FDR&amp;lt;0.25 were considered as significant. NES, normalized enrichment score; NOM, nominal; FDR, false discovery rate; JAK, Janus kinase; KEGG, Kyoto Encyclopedia of Genes and Genomes.&lt;/p&gt;
&lt;h2 id=&#34;discussion&#34;&gt;Discussion&lt;/h2&gt;
&lt;p&gt;BC is the most common malignancy of the urinary system, and ~90% of BC cases are urothelial carcinoma (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b5-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;5&lt;/a&gt;). Furthermore, BC can be low grade or high grade and can also be divided into MIBC and NMIBC; low grade BC rarely invades the muscular wall of the bladder and patients rarely succumb to low grade BC, while high grade BC is more likely to result in mortality (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b6-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;6&lt;/a&gt;). Furthermore, patients with NMIBC exhibit a favorable outcome (5-year overall survival of 95 vs. 69% in MIBC) (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b36-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;36&lt;/a&gt;). However, 70% of patients with BC will experience recurrence following initial treatment (surgery, radiotherapy or chemotherapy), including 30% out of the 70% of patients presenting with muscle invasive disease (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b37-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;37&lt;/a&gt;). In addition, cancer recurrence and progression lead to a higher disease stage, ending therefore in a less favorable outcome (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b38-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;38&lt;/a&gt;). Currently, the etiology of muscle invasion and high-grade progression in BC remains unknown. It is therefore crucial to identify an effective biomarker that could predict muscle invasion, high grade and prognosis in patients with BC.&lt;/p&gt;
&lt;p&gt;To the best of our knowledge, ST3GAL5 expression and its effect on muscle invasion, cancer grade and prognosis in patients with BLCA have not yet been investigated. The present study investigated therefore the potential role of ST3GAL5 in BLCA. In this study, bioinformatics analysis of multiple independent public databases was performed. The results demonstrated that ST3GAL5 was downregulated in various types of cancer, including BC, and that its expression in BLCA tissues was lower compared with healthy bladder tissues. In addition, ST3GAL5 downregulation was positively associated with muscle invasion, high grade and a poor prognosis in patients with BLCA. Collectively, these findings indicated that ST3GAL5 may be considered as a tumor suppressor gene in BLCA, and may therefore inhibit the progression of BC to MIBC and high grade BLCA. These results also highlighted the potential role of ST3GAL5 as a therapeutic target in BC. However, further investigation is required to determine the underlying mechanisms of ST3GAL5 in BC progression and in the prognosis of patients with BC.&lt;/p&gt;
&lt;p&gt;The association between ST3GAL5 expression, promoter methylation level and the clinicopathological characteristics of patients with BLCA was examined using TCGA data from the Xena browser. The results demonstrated that ST3GAL5 expression was downregulated in high stages and moderate nodal metastasis status compared with healthy bladder tissues. However, the level of ST3GAL5 promoter methylation was significantly decreased in BCLA tissues compared with healthy bladder tissues regardless of the patients&#39; clinicopathological characteristics, including cancer stage, ethnicity, sex, age, weight, smoking status, nodal metastasis status and histological subtype. Furthermore, analysis of ST3GAL5 expression and DNA methylation status indicated that ST3GAL5 gene expression may be associated with certain CpG island sites. CpG islands are CG-rich stretches in the genome concentrated near transcription start sites; in normal cells they are protected and therefore are in a non-methylated state, but in tumors they are specifically methylated. These findings suggested therefore that ST3GAL5 promoter methylation may be associated with the clinicopathological characteristics of patients with BC.&lt;/p&gt;
&lt;p&gt;ST3GAL5 is a protein that catalyzes the formation of ganglioside GM3 (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b7-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;7&lt;/a&gt;). ST3GAL5 is upregulated in several types of cancer, such as lung and brain cancer, and melanoma, and can serve as a tumor-associated carbohydrate antigen in immunotherapy for cancer (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b9-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;9&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b10-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;10&lt;/a&gt;). Furthermore, ST3GAL5, which encodes GM3, inhibits tumor cell proliferation through angiogenesis inhibition or decrease in cell motility (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b9-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;9&lt;/a&gt;). Previous studies reported that ST3GAL5 exerts some anti-proliferative effects in colon cancer (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b39-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;39&lt;/a&gt;), breast cancer (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b40-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;40&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b41-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;41&lt;/a&gt;), liver cancer (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b42-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;42&lt;/a&gt;) and other types of tumor (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b9-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;9&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b10-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;10&lt;/a&gt;). Although some studies demonstrated that ST3GAL5 has anti-tumor effects in human bladder cancer (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b11-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;11&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b14-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;14&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b39-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;39&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b43-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;43&lt;/a&gt;), the underlying mechanisms remain unknown. Furthermore, it was reported that ST3GAL5 effects could be associated with tumor cell apoptosis and angiogenesis inhibition (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b9-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;9&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b12-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;12&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b44-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;44&lt;/a&gt;). However, the expression profile and functional role of ST3GAL5 in BLCA remain unknown.&lt;/p&gt;
&lt;p&gt;In the present study, the biological effect of ST3GAL5 in BLCA was investigated by using bioinformatics analysis of multiple public databases. Co-expressed genes that were positively associated with ST3GAL5 expression were identified in three public databases, and intersecting genes from all databases were considered to be significantly co-expressed genes. R packages were then used to identify the signaling pathways associated with the genes that were positively co-expressed with ST3GAL5 in BLCA samples. Furthermore, from the perspective of functional classification, GO enrichment analysis of BP, CC and MF was performed on ST3GAL5 and its co-expressed genes. The results from KEGG pathway analysis revealed that the ‘TGF-β signaling pathway’ was significantly associated with ST3GAL5 expression. The deregulation of this pathway has been reported to result in tumor progression (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b45-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;45&lt;/a&gt;). In healthy and early-stage cancer, such as breast and prostate cancer cells, the TGF-β pathway exerts tumor-suppressive properties; however, its activation in late-stage cancer can promote tumor progression, via metastasis and chemoresistance (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b45-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;45&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b46-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;46&lt;/a&gt;). Furthermore, the dual function and pleiotropic nature of TGF-β signaling makes of it a challenging target; therefore, careful therapeutic dosage of TGF-β drugs and careful patient selection are required (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b46-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;46&lt;/a&gt;). In the present study, although ST3GAL5 expression was downregulated in BLCA tissues compared with healthy bladder tissues, ST3GAL5 expression was significantly downregulated in high grade and advanced stage BLCA in multiple databases. The significant downregulation in high grade and advanced stage BLCA may due to the associated activation of ST3GAL5 and its co-expressed genes following the increase in TGF-β signaling transduction. Another pathway associated with ST3GAL5 expression was ‘carbon metabolism’. Cells require one-carbon units for nucleotide synthesis, methylation and reductive metabolism, which support the high proliferative rate of cancer cells (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b47-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;47&lt;/a&gt;). A previous study reported that polymorphisms in one-carbon metabolism and susceptibility to BC suggested that variation in glutathione synthesis may contribute to the risk of BC (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b48-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;48&lt;/a&gt;). In the present study, Reactome pathway analysis demonstrated that the main pathway associated with ST3GAL5 expression was ‘protein localization’, and previous studies reported that changes in subcellular localization of tumor-associated proteins can influence protein structure and biological function, which are associated with tumorigenesis, tumor progression and patient prognosis (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b49-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;49&lt;/a&gt;–&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b52-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;52&lt;/a&gt;). Another pathway associated with ST3GAL5 expression was ‘neutrophil degranulation’. Neutrophils have been shown to be the first responders to inflammation and infection (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b53-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;53&lt;/a&gt;). The role of neutrophils in cancer is multifactorial, but is not fully understood. Furthermore, neutrophils reflect a state of host inflammation, which is a hallmark of cancer (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b54-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;54&lt;/a&gt;), and can participate in different stages of the oncogenic process including tumor initiation, growth, proliferation and metastasis (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b55-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;55&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b56-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;56&lt;/a&gt;). Neutrophil granule proteins released upon cell activation have also been associated with tumor progression, and this differential granule mobilization may allow neutrophils and possibly associated cancer cells to exit the bloodstream and enter inflamed and infected tissues (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b53-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;53&lt;/a&gt;). Since neutrophils are immune cells, tumor immunity must also be considered in order to predict the prognosis of patients with BC. Takeuchi &lt;em&gt;et al&lt;/em&gt; (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b55-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;55&lt;/a&gt;), reported that the Tumour-associated macrophage polarized M2 phenotype influences microangiogenesis, pathological outcome, tumor grade and tumor invasiveness in BC. In the present study, GO analysis of the BP and MF domains identified co-enzyme involvement in BP and MF, suggesting that co-enzymes may serve an important role in the tumorigenesis and tumor progression of BC. However, further &lt;em&gt;in vitro&lt;/em&gt; and &lt;em&gt;in vivo&lt;/em&gt; studies are required to elucidate the biological role of ST3GAL5 in BC. Taken together, these findings highlighted the important role of ST3GAL5 and its co-expressed genes in various carcinogenic processes.&lt;/p&gt;
&lt;p&gt;A large BLCA dataset from the GEO database was investigated in the present study. According to the mean value of ST3GAL5 expression, the dataset was divided into low- and high-expression groups, and GSEA was used to compare the two groups. The results identified three tumor-associated pathways that were associated with ST3GAL5 in BLCA, the ‘NLR signaling pathway’, ‘cytokine-cytokine receptor interaction’ and ‘JAK-STAT signaling pathway’. NLR signaling pathway is an immunology-signaling pathway, in which cytosolic NLRs are associated with certain diseases, including infections, cancer and autoimmune and inflammatory disorders (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b57-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;57&lt;/a&gt;). Furthermore, NLRs and their downstream signaling components can engage in an intricate crosstalk with cell death and autophagy pathways, which are critical processes for cancer progression (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b58-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;58&lt;/a&gt;). Kent and Blander (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b57-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;57&lt;/a&gt;) reported that chronic inflammation resulting from the activated NLRs signaling pathway is a powerful driver of carcinogenesis, which promotes gene mutation, tumor growth and progression. In the present study, results from KEGG analysis suggested that lower expression of ST3GAL5 were enriched in the ‘NLR signaling pathway’. Ozaki and Leonard (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b59-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;59&lt;/a&gt;) demonstrated that cytokines are crucial intercellular regulators and mobilizers of cells that are involved in innate and adaptive inflammatory host defenses, cell proliferation, cell differentiation, cell death, angiogenesis, and development and repair processes associated with the restoration of homeostasis. In the current study, the ‘cytokine-cytokine receptor interaction’ was positively associated with lower ST3GAL5 expression, suggesting that ST3GAL5 downregulation may promote oncogenesis by affecting the immune status of patients with BC. The JAK-STAT pathway is an essential signaling pathway involved with numerous cytokines and proliferation factors in mammals (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b60-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;60&lt;/a&gt;). Previous studies (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b60-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;60&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b61-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;61&lt;/a&gt;) assessing the JAK-STAT signaling pathway reported highly conserved programs linking cytokine signaling to the regulation of essential cellular mechanisms, including cell proliferation, cell invasion, cell survival, inflammation and immunity. Furthermore, aberrant active regulation of JAK-STAT signaling pathway has been reported to contribute to cancer progression and development of metastasis (&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b60-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;60&lt;/a&gt;,&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285741/#b61-ol-0-0-11597&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;61&lt;/a&gt;). In the present study, results from pathway analysis suggested that the low expression of ST3GAL5 may positively affect the progression of BLCA via tumor immunity, cytokine interaction and cytokine transduction. The results from this study suggested that immunotherapy may be used in the treatment of BLCA, and that ST3GAL5 may be considered as a novel target and potential biomarker in BLCA.&lt;/p&gt;
&lt;h2 id=&#34;acknowledgements&#34;&gt;Acknowledgements&lt;/h2&gt;
&lt;p&gt;Not applicable.&lt;/p&gt;
&lt;h2 id=&#34;glossary&#34;&gt;Glossary&lt;/h2&gt;
&lt;h4 id=&#34;abbreviations&#34;&gt;Abbreviations&lt;/h4&gt;
&lt;table&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th&gt;BC&lt;/th&gt;
&lt;th&gt;bladder cancer&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td&gt;BLCA&lt;/td&gt;
&lt;td&gt;bladder urothelial carcinoma&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;MIBC&lt;/td&gt;
&lt;td&gt;muscle invasive bladder cancer&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;NMIBC&lt;/td&gt;
&lt;td&gt;non-muscle invasive bladder cancer&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;h2 id=&#34;funding&#34;&gt;Funding&lt;/h2&gt;
&lt;p&gt;The present study was supported by the Key Scientific and Technological Projects of Xinjiang Production and Construction Corps (grant no. 2018AB023).&lt;/p&gt;
&lt;h2 id=&#34;availability-of-data-and-materials&#34;&gt;Availability of data and materials&lt;/h2&gt;
&lt;p&gt;The datasets generated and/or analyzed during the present study are available in the GEO (&lt;a href=&#34;http://www.ncbi.nlm.nih.gov/geo&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;www.ncbi.nlm.nih.gov/geo&lt;/a&gt;), Oncomine (&lt;a href=&#34;http://www.oncomine.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;www.oncomine.org&lt;/a&gt;) and TGCA (&lt;a href=&#34;http://cancergenome.nih.gov/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;cancergenome.nih.gov&lt;/a&gt;) repositories.&lt;/p&gt;
&lt;h2 id=&#34;authors-contributions&#34;&gt;Authors&#39; contributions&lt;/h2&gt;
&lt;p&gt;JL and QW participated in the design of the present study, performed the statistical analysis and drafted the manuscript. SO, ZN and GD performed the study and collected background information and data. SO was a major contributor in writing the manuscript. All authors read and approved the final manuscript.&lt;/p&gt;
&lt;h2 id=&#34;ethics-approval-and-consent-to-participate&#34;&gt;Ethics approval and consent to participate&lt;/h2&gt;
&lt;p&gt;Not applicable.&lt;/p&gt;
&lt;h2 id=&#34;patient-consent-for-publication&#34;&gt;Patient consent for publication&lt;/h2&gt;
&lt;p&gt;Not applicable.&lt;/p&gt;
&lt;h2 id=&#34;competing-interests&#34;&gt;Competing interests&lt;/h2&gt;
&lt;p&gt;The authors declare that they have no competing interests.&lt;/p&gt;
&lt;h2 id=&#34;references&#34;&gt;References&lt;/h2&gt;
&lt;ol&gt;
&lt;li&gt;Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387. doi: 10.1016/j.ejca.2018.07.005. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/30100160&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2Fj.ejca.2018.07.005&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Eur&amp;#43;J&amp;#43;Cancer&amp;amp;title=Cancer&amp;#43;incidence&amp;#43;and&amp;#43;mortality&amp;#43;patterns&amp;#43;in&amp;#43;Europe:&amp;#43;Estimates&amp;#43;for&amp;#43;40&amp;#43;countries&amp;#43;and&amp;#43;25&amp;#43;major&amp;#43;cancers&amp;#43;in&amp;#43;2018&amp;amp;author=J&amp;#43;Ferlay&amp;amp;author=M&amp;#43;Colombet&amp;amp;author=I&amp;#43;Soerjomataram&amp;amp;author=T&amp;#43;Dyba&amp;amp;author=G&amp;#43;Randi&amp;amp;volume=103&amp;amp;publication_year=2018&amp;amp;pages=356-387&amp;amp;pmid=30100160&amp;amp;doi=10.1016/j.ejca.2018.07.005&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, corp-author. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Lond Engl. 2016;388:1545–1602. doi: 10.1016/S0140-6736(16)31678-6. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055577/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/27733282&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2FS0140-6736%2816%2931678-6&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Lancet&amp;#43;Lond&amp;#43;Engl&amp;amp;title=Global,&amp;#43;regional,&amp;#43;and&amp;#43;national&amp;#43;incidence,&amp;#43;prevalence,&amp;#43;and&amp;#43;years&amp;#43;lived&amp;#43;with&amp;#43;disability&amp;#43;for&amp;#43;310&amp;#43;diseases&amp;#43;and&amp;#43;injuries,&amp;#43;1990%E2%80%932015:&amp;#43;A&amp;#43;systematic&amp;#43;analysis&amp;#43;for&amp;#43;the&amp;#43;Global&amp;#43;Burden&amp;#43;of&amp;#43;Disease&amp;#43;Study&amp;#43;2015&amp;amp;volume=388&amp;amp;publication_year=2016&amp;amp;pages=1545-1602&amp;amp;doi=10.1016/S0140-6736%2816%2931678-6&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. doi: 10.3322/caac.21551. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/30620402&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.3322%2Fcaac.21551&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=CA&amp;#43;Cancer&amp;#43;J&amp;#43;Clin&amp;amp;title=Cancer&amp;#43;statistics,&amp;#43;2019&amp;amp;author=RL&amp;#43;Siegel&amp;amp;author=KD&amp;#43;Miller&amp;amp;author=A&amp;#43;Jemal&amp;amp;volume=69&amp;amp;publication_year=2019&amp;amp;pages=7-34&amp;amp;pmid=30620402&amp;amp;doi=10.3322/caac.21551&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, Vecchia CL, Shariat S, Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012;63:234–241. doi: 10.1016/j.eururo.2012.07.033. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/22877502&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2Fj.eururo.2012.07.033&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Eur&amp;#43;Urol&amp;amp;title=Epidemiology&amp;#43;and&amp;#43;risk&amp;#43;factors&amp;#43;of&amp;#43;urothelial&amp;#43;bladder&amp;#43;cancer&amp;amp;author=M&amp;#43;Burger&amp;amp;author=JW&amp;#43;Catto&amp;amp;author=G&amp;#43;Dalbagni&amp;amp;author=HB&amp;#43;Grossman&amp;amp;author=H&amp;#43;Herr&amp;amp;volume=63&amp;amp;publication_year=2012&amp;amp;pages=234-241&amp;amp;pmid=22877502&amp;amp;doi=10.1016/j.eururo.2012.07.033&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24:730–734. doi: 10.1111/iju.13376. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/28543959&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1111%2Fiju.13376&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Int&amp;#43;J&amp;#43;Urol&amp;amp;title=Epidemiology&amp;#43;of&amp;#43;urothelial&amp;#43;carcinoma&amp;amp;author=J&amp;#43;Miyazaki&amp;amp;author=H&amp;#43;Nishiyama&amp;amp;volume=24&amp;amp;publication_year=2017&amp;amp;pages=730-734&amp;amp;pmid=28543959&amp;amp;doi=10.1111/iju.13376&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Witjes JA, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017;71:462–475. doi: 10.1016/j.eururo.2016.06.020. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/27375033&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2Fj.eururo.2016.06.020&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Eur&amp;#43;Urol&amp;amp;title=Updated&amp;#43;2016&amp;#43;EAU&amp;#43;Guidelines&amp;#43;on&amp;#43;Muscle-invasive&amp;#43;and&amp;#43;Metastatic&amp;#43;Bladder&amp;#43;Cancer&amp;amp;author=JA&amp;#43;Witjes&amp;amp;author=T&amp;#43;Lebret&amp;amp;author=EM&amp;#43;Comp%C3%A9rat&amp;amp;author=NC&amp;#43;Cowan&amp;amp;author=M&amp;#43;De&amp;#43;Santis&amp;amp;volume=71&amp;amp;publication_year=2017&amp;amp;pages=462-475&amp;amp;pmid=27375033&amp;amp;doi=10.1016/j.eururo.2016.06.020&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Berselli P, Zava S, Sottocornola E, Milani S, Berra B, Colombo I. Human GM3 synthase: A new mRNA variant encodes an NH2-terminal extended form of the protein. Biochimica Biophysica Acta. 2006;1759:348–358. doi: 10.1016/j.bbaexp.2006.07.001. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/16934889&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2Fj.bbaexp.2006.07.001&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Biochimica&amp;#43;Biophysica&amp;#43;Acta&amp;amp;title=Human&amp;#43;GM3&amp;#43;synthase:&amp;#43;A&amp;#43;new&amp;#43;mRNA&amp;#43;variant&amp;#43;encodes&amp;#43;an&amp;#43;NH2-terminal&amp;#43;extended&amp;#43;form&amp;#43;of&amp;#43;the&amp;#43;protein&amp;amp;author=P&amp;#43;Berselli&amp;amp;author=S&amp;#43;Zava&amp;amp;author=E&amp;#43;Sottocornola&amp;amp;author=S&amp;#43;Milani&amp;amp;author=B&amp;#43;Berra&amp;amp;volume=1759&amp;amp;publication_year=2006&amp;amp;pages=348-358&amp;amp;doi=10.1016/j.bbaexp.2006.07.001&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Inokuchi JI, Inamori KI, Kabayama K, Nagafuku M, Uemura S, Go S, Suzuki A, Ohno I, Kanoh H, Shishido F. Biology of GM3 Ganglioside. Prog Mol Biol Transl. 2018;156:151–195. doi: 10.1016/bs.pmbts.2017.10.004. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/29747813&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2Fbs.pmbts.2017.10.004&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Prog&amp;#43;Mol&amp;#43;Biol&amp;#43;Transl&amp;amp;title=Biology&amp;#43;of&amp;#43;GM3&amp;#43;Ganglioside&amp;amp;author=JI&amp;#43;Inokuchi&amp;amp;author=KI&amp;#43;Inamori&amp;amp;author=K&amp;#43;Kabayama&amp;amp;author=M&amp;#43;Nagafuku&amp;amp;author=S&amp;#43;Uemura&amp;amp;volume=156&amp;amp;publication_year=2018&amp;amp;pages=151-195&amp;amp;doi=10.1016/bs.pmbts.2017.10.004&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Zheng C, Terreni M, Sollogoub M, Zhang Y. Ganglioside GM3 and its role in cancer. Curr Med Chem. 2019;26:2933–2947. doi: 10.2174/0929867325666180129100619. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/29376491&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.2174%2F0929867325666180129100619&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Curr&amp;#43;Med&amp;#43;Chem&amp;amp;title=Ganglioside&amp;#43;GM3&amp;#43;and&amp;#43;its&amp;#43;role&amp;#43;in&amp;#43;cancer&amp;amp;author=C&amp;#43;Zheng&amp;amp;author=M&amp;#43;Terreni&amp;amp;author=M&amp;#43;Sollogoub&amp;amp;author=Y&amp;#43;Zhang&amp;amp;volume=26&amp;amp;publication_year=2019&amp;amp;pages=2933-2947&amp;amp;pmid=29376491&amp;amp;doi=10.2174/0929867325666180129100619&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Hakomori SI, Handa K. GM3 and cancer. Glycoconjugate J. 2015;32:1–8. doi: 10.1007/s10719-014-9572-4. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/25613425&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1007%2Fs10719-014-9572-4&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Glycoconjugate&amp;#43;J&amp;amp;title=GM3&amp;#43;and&amp;#43;cancer&amp;amp;author=SI&amp;#43;Hakomori&amp;amp;author=K&amp;#43;Handa&amp;amp;volume=32&amp;amp;publication_year=2015&amp;amp;pages=1-8&amp;amp;doi=10.1007/s10719-014-9572-4&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Satoh M, Ito A, Nojiri H, Handa K, Numahata K, Ohyama C, Saito S, Hoshi S, Hakomori SI. Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells. Int J Oncol. 2001;19:723–731. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/11562747&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Int&amp;#43;J&amp;#43;Oncol&amp;amp;title=Enhanced&amp;#43;GM3&amp;#43;expression,&amp;#43;associated&amp;#43;with&amp;#43;decreased&amp;#43;invasiveness,&amp;#43;is&amp;#43;induced&amp;#43;by&amp;#43;brefeldin&amp;#43;A&amp;#43;in&amp;#43;bladder&amp;#43;cancer&amp;#43;cells&amp;amp;author=M&amp;#43;Satoh&amp;amp;author=A&amp;#43;Ito&amp;amp;author=H&amp;#43;Nojiri&amp;amp;author=K&amp;#43;Handa&amp;amp;author=K&amp;#43;Numahata&amp;amp;volume=19&amp;amp;publication_year=2001&amp;amp;pages=723-731&amp;amp;pmid=11562747&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Kawashima N, Nishimiya Y, Takahata S, Nakayama KI. Induction of Glycosphingolipid GM3 expression by valproic acid suppresses cancer cell growth. J Biol Chem. 2016;291:21424–21433. doi: 10.1074/jbc.M116.751503. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076815/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/27539856&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1074%2Fjbc.M116.751503&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=J&amp;#43;Biol&amp;#43;Chem&amp;amp;title=Induction&amp;#43;of&amp;#43;Glycosphingolipid&amp;#43;GM3&amp;#43;expression&amp;#43;by&amp;#43;valproic&amp;#43;acid&amp;#43;suppresses&amp;#43;cancer&amp;#43;cell&amp;#43;growth&amp;amp;author=N&amp;#43;Kawashima&amp;amp;author=Y&amp;#43;Nishimiya&amp;amp;author=S&amp;#43;Takahata&amp;amp;author=KI&amp;#43;Nakayama&amp;amp;volume=291&amp;amp;publication_year=2016&amp;amp;pages=21424-21433&amp;amp;pmid=27539856&amp;amp;doi=10.1074/jbc.M116.751503&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Ohyama C. Glycosylation in bladder cancer. Int J Clin Oncol. 2008;13:308–313. doi: 10.1007/s10147-008-0809-8. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/18704630&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1007%2Fs10147-008-0809-8&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Int&amp;#43;J&amp;#43;Clin&amp;#43;Oncol&amp;amp;title=Glycosylation&amp;#43;in&amp;#43;bladder&amp;#43;cancer&amp;amp;author=C&amp;#43;Ohyama&amp;amp;volume=13&amp;amp;publication_year=2008&amp;amp;pages=308-313&amp;amp;pmid=18704630&amp;amp;doi=10.1007/s10147-008-0809-8&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207–210. doi: 10.1093/nar/30.1.207. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC99122/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/11752295&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1093%2Fnar%2F30.1.207&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Nucleic&amp;#43;Acids&amp;#43;Res&amp;amp;title=Gene&amp;#43;Expression&amp;#43;Omnibus:&amp;#43;NCBI&amp;#43;gene&amp;#43;expression&amp;#43;and&amp;#43;hybridization&amp;#43;array&amp;#43;data&amp;#43;repository&amp;amp;author=R&amp;#43;Edgar&amp;amp;author=M&amp;#43;Domrachev&amp;amp;author=AE&amp;#43;Lash&amp;amp;volume=30&amp;amp;publication_year=2002&amp;amp;pages=207-210&amp;amp;pmid=11752295&amp;amp;doi=10.1093/nar/30.1.207&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9:166–180. doi: 10.1593/neo.07112. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1813932/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/17356713&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1593%2Fneo.07112&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Neoplasia&amp;amp;title=Oncomine&amp;#43;3.0:&amp;#43;Genes,&amp;#43;pathways,&amp;#43;and&amp;#43;networks&amp;#43;in&amp;#43;a&amp;#43;collection&amp;#43;of&amp;#43;18,000&amp;#43;cancer&amp;#43;gene&amp;#43;expression&amp;#43;profiles&amp;amp;author=DR&amp;#43;Rhodes&amp;amp;author=S&amp;#43;Kalyana-Sundaram&amp;amp;author=V&amp;#43;Mahavisno&amp;amp;author=R&amp;#43;Varambally&amp;amp;author=J&amp;#43;Yu&amp;amp;volume=9&amp;amp;publication_year=2007&amp;amp;pages=166-180&amp;amp;pmid=17356713&amp;amp;doi=10.1593/neo.07112&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pander A, Chinnaiyan AM. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6:1–6. doi: 10.1016/S1476-5586(04)80047-2. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1635162/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/15068665&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2FS1476-5586%2804%2980047-2&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Neoplasia&amp;amp;title=ONCOMINE:&amp;#43;A&amp;#43;cancer&amp;#43;microarray&amp;#43;database&amp;#43;and&amp;#43;integrated&amp;#43;data-mining&amp;#43;platform&amp;amp;author=DR&amp;#43;Rhodes&amp;amp;author=J&amp;#43;Yu&amp;amp;author=K&amp;#43;Shanker&amp;amp;author=N&amp;#43;Deshpande&amp;amp;author=R&amp;#43;Varambally&amp;amp;volume=6&amp;amp;publication_year=2004&amp;amp;pages=1-6&amp;amp;pmid=15068665&amp;amp;doi=10.1016/S1476-5586%2804%2980047-2&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al. Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy. Genome Biol. 2016;17:174. doi: 10.1186/s13059-016-1028-7. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993001/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/27549193&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1186%2Fs13059-016-1028-7&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Genome&amp;#43;Biol&amp;amp;title=Comprehensive&amp;#43;analyses&amp;#43;of&amp;#43;tumor&amp;#43;immunity:&amp;#43;Implications&amp;#43;for&amp;#43;cancer&amp;#43;immunotherapy&amp;amp;author=B&amp;#43;Li&amp;amp;author=E&amp;#43;Severson&amp;amp;author=JC&amp;#43;Pignon&amp;amp;author=H&amp;#43;Zhao&amp;amp;author=T&amp;#43;Li&amp;amp;volume=17&amp;amp;publication_year=2016&amp;amp;pages=174&amp;amp;pmid=27549193&amp;amp;doi=10.1186/s13059-016-1028-7&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108–e110. doi: 10.1158/0008-5472.CAN-17-0307. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042652/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/29092952&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1158%2F0008-5472.CAN-17-0307&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Cancer&amp;#43;Res&amp;amp;title=TIMER:&amp;#43;A&amp;#43;web&amp;#43;server&amp;#43;for&amp;#43;comprehensive&amp;#43;analysis&amp;#43;of&amp;#43;tumor-infiltrating&amp;#43;immune&amp;#43;cells&amp;amp;author=T&amp;#43;Li&amp;amp;author=J&amp;#43;Fan&amp;amp;author=B&amp;#43;Wang&amp;amp;author=N&amp;#43;Traugh&amp;amp;author=Q&amp;#43;Chen&amp;amp;volume=77&amp;amp;publication_year=2017&amp;amp;pages=e108-e110&amp;amp;pmid=29092952&amp;amp;doi=10.1158/0008-5472.CAN-17-0307&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Park SJ, Yoon BH, Kim SK, Kim SY. GENT2: An updated gene expression database for normal and tumor tissues. BMC Med Genomics. 2019;12(Suppl 5):101. doi: 10.1186/s12920-019-0514-7. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624177/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/31296229&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1186%2Fs12920-019-0514-7&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=BMC&amp;#43;Med&amp;#43;Genomics&amp;amp;title=GENT2:&amp;#43;An&amp;#43;updated&amp;#43;gene&amp;#43;expression&amp;#43;database&amp;#43;for&amp;#43;normal&amp;#43;and&amp;#43;tumor&amp;#43;tissues&amp;amp;author=SJ&amp;#43;Park&amp;amp;author=BH&amp;#43;Yoon&amp;amp;author=SK&amp;#43;Kim&amp;amp;author=SY&amp;#43;Kim&amp;amp;volume=12&amp;amp;issue=Suppl&amp;#43;5&amp;amp;publication_year=2019&amp;amp;pages=101&amp;amp;pmid=31296229&amp;amp;doi=10.1186/s12920-019-0514-7&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Shin G, Kang TW, Yang S, Baek SJ, Jeong YS, Kim SY. GENT: Gene expression database of normal and tumor tissues. Cancer Informatics. 2011;10:149–157. doi: 10.4137/CIN.S7226. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118449/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/21695066&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.4137%2FCIN.S7226&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Cancer&amp;#43;Informatics&amp;amp;title=GENT:&amp;#43;Gene&amp;#43;expression&amp;#43;database&amp;#43;of&amp;#43;normal&amp;#43;and&amp;#43;tumor&amp;#43;tissues&amp;amp;author=G&amp;#43;Shin&amp;amp;author=TW&amp;#43;Kang&amp;amp;author=S&amp;#43;Yang&amp;amp;author=SJ&amp;#43;Baek&amp;amp;author=YS&amp;#43;Jeong&amp;amp;volume=10&amp;amp;publication_year=2011&amp;amp;pages=149-157&amp;amp;pmid=21695066&amp;amp;doi=10.4137/CIN.S7226&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Goldman M, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, et al. The UCSC Xena platform for public and private cancer genomics data visualization and interpretation. 2019 Biorxiv 326470. [&lt;a href=&#34;https://scholar.google.com/scholar?q=Goldman&amp;#43;M&amp;#43;Craft&amp;#43;B&amp;#43;Hastie&amp;#43;M&amp;#43;Repe%C4%8Dka&amp;#43;K&amp;#43;McDade&amp;#43;F&amp;#43;Kamath&amp;#43;A&amp;#43;Banerjee&amp;#43;A&amp;#43;Luo&amp;#43;Y&amp;#43;Rogers&amp;#43;D&amp;#43;The&amp;#43;UCSC&amp;#43;Xena&amp;#43;platform&amp;#43;for&amp;#43;public&amp;#43;and&amp;#43;private&amp;#43;cancer&amp;#43;genomics&amp;#43;data&amp;#43;visualization&amp;#43;and&amp;#43;interpretation&amp;#43;Biorxiv&amp;#43;326470&amp;#43;2019&amp;#43;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–W102. doi: 10.1093/nar/gkx247. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570223/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/28407145&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1093%2Fnar%2Fgkx247&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Nucleic&amp;#43;Acids&amp;#43;Res&amp;amp;title=GEPIA:&amp;#43;A&amp;#43;web&amp;#43;server&amp;#43;for&amp;#43;cancer&amp;#43;and&amp;#43;normal&amp;#43;gene&amp;#43;expression&amp;#43;profiling&amp;#43;and&amp;#43;interactive&amp;#43;analyses&amp;amp;author=Z&amp;#43;Tang&amp;amp;author=C&amp;#43;Li&amp;amp;author=B&amp;#43;Kang&amp;amp;author=G&amp;#43;Gao&amp;amp;author=C&amp;#43;Li&amp;amp;volume=45&amp;amp;publication_year=2017&amp;amp;pages=W98-W102&amp;amp;pmid=28407145&amp;amp;doi=10.1093/nar/gkx247&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Anaya J, Reon B, Chen WM, Bekiranov S, Dutta A. A pan-cancer analysis of prognostic genes. Peer J. 2016;3:e1499. doi: 10.7717/peerj.1499. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815555/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/27047702&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.7717%2Fpeerj.1499&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Peer&amp;#43;J&amp;amp;title=A&amp;#43;pan-cancer&amp;#43;analysis&amp;#43;of&amp;#43;prognostic&amp;#43;genes&amp;amp;author=J&amp;#43;Anaya&amp;amp;author=B&amp;#43;Reon&amp;amp;author=WM&amp;#43;Chen&amp;amp;author=S&amp;#43;Bekiranov&amp;amp;author=A&amp;#43;Dutta&amp;amp;volume=3&amp;amp;publication_year=2016&amp;amp;pages=e1499&amp;amp;pmid=27047702&amp;amp;doi=10.7717/peerj.1499&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3. doi: 10.1186/1476-4598-9-3. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821358/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/20059769&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1186%2F1476-4598-9-3&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Mol&amp;#43;Cancer&amp;amp;title=Predictive&amp;#43;value&amp;#43;of&amp;#43;progression-related&amp;#43;gene&amp;#43;classifier&amp;#43;in&amp;#43;primary&amp;#43;non-muscle&amp;#43;invasive&amp;#43;bladder&amp;#43;cancer&amp;amp;author=WJ&amp;#43;Kim&amp;amp;author=EJ&amp;#43;Kim&amp;amp;author=SK&amp;#43;Kim&amp;amp;author=YJ&amp;#43;Kim&amp;amp;author=YS&amp;#43;Ha&amp;amp;volume=9&amp;amp;publication_year=2010&amp;amp;pages=3&amp;amp;pmid=20059769&amp;amp;doi=10.1186/1476-4598-9-3&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, Michor F. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012;18:1323–1333. doi: 10.1158/1078-0432.CCR-11-2271. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569085/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/22228636&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1158%2F1078-0432.CCR-11-2271&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Clin&amp;#43;Cancer&amp;#43;Res&amp;amp;title=Combination&amp;#43;of&amp;#43;a&amp;#43;novel&amp;#43;gene&amp;#43;expression&amp;#43;signature&amp;#43;with&amp;#43;a&amp;#43;clinical&amp;#43;nomogram&amp;#43;improves&amp;#43;the&amp;#43;prediction&amp;#43;of&amp;#43;survival&amp;#43;in&amp;#43;high-risk&amp;#43;bladder&amp;#43;cancer&amp;amp;author=M&amp;#43;Riester&amp;amp;author=JM&amp;#43;Taylor&amp;amp;author=A&amp;#43;Feifer&amp;amp;author=T&amp;#43;Koppie&amp;amp;author=JE&amp;#43;Rosenberg&amp;amp;volume=18&amp;amp;publication_year=2012&amp;amp;pages=1323-1333&amp;amp;pmid=22228636&amp;amp;doi=10.1158/1078-0432.CCR-11-2271&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O&amp;rsquo;Brien R, Schutz FA, et al. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014;20:1873–1883. doi: 10.1158/1078-0432.CCR-13-0759. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975677/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/24486590&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1158%2F1078-0432.CCR-13-0759&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Clin&amp;#43;Cancer&amp;#43;Res&amp;amp;title=Integrative&amp;#43;analysis&amp;#43;of&amp;#43;1q23.3&amp;#43;copy-number&amp;#43;gain&amp;#43;in&amp;#43;metastatic&amp;#43;urothelial&amp;#43;carcinoma&amp;amp;author=M&amp;#43;Riester&amp;amp;author=L&amp;#43;Werner&amp;amp;author=J&amp;#43;Bellmunt&amp;amp;author=S&amp;#43;Selvarajah&amp;amp;author=EA&amp;#43;Guancial&amp;amp;volume=20&amp;amp;publication_year=2014&amp;amp;pages=1873-1883&amp;amp;pmid=24486590&amp;amp;doi=10.1158/1078-0432.CCR-13-0759&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, Chu IS. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 2010;28:2660–2667. doi: 10.1200/JCO.2009.25.0977. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/20421545&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1200%2FJCO.2009.25.0977&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=J&amp;#43;Clin&amp;#43;Oncol&amp;amp;title=Expression&amp;#43;signature&amp;#43;of&amp;#43;E2F1&amp;#43;and&amp;#43;its&amp;#43;associated&amp;#43;genes&amp;#43;predict&amp;#43;superficial&amp;#43;to&amp;#43;invasive&amp;#43;progression&amp;#43;of&amp;#43;bladder&amp;#43;tumors&amp;amp;author=JS&amp;#43;Lee&amp;amp;author=SH&amp;#43;Leem&amp;amp;author=SY&amp;#43;Lee&amp;amp;author=SC&amp;#43;Kim&amp;amp;author=ES&amp;#43;Park&amp;amp;volume=28&amp;amp;publication_year=2010&amp;amp;pages=2660-2667&amp;amp;pmid=20421545&amp;amp;doi=10.1200/JCO.2009.25.0977&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Pejavar S, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005;11:4044–4055. doi: 10.1158/1078-0432.CCR-04-2409. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/15930339&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1158%2F1078-0432.CCR-04-2409&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Clin&amp;#43;Cancer&amp;#43;Res&amp;amp;title=Bladder&amp;#43;cancer&amp;#43;outcome&amp;#43;and&amp;#43;subtype&amp;#43;classification&amp;#43;by&amp;#43;gene&amp;#43;expression&amp;amp;author=E&amp;#43;Blaveri&amp;amp;author=JP&amp;#43;Simko&amp;amp;author=JE&amp;#43;Korkola&amp;amp;author=JL&amp;#43;Brewer&amp;amp;author=F&amp;#43;Baehner&amp;amp;volume=11&amp;amp;publication_year=2005&amp;amp;pages=4044-4055&amp;amp;pmid=15930339&amp;amp;doi=10.1158/1078-0432.CCR-04-2409&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24:778–789. doi: 10.1200/JCO.2005.03.2375. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/16432078&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1200%2FJCO.2005.03.2375&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=J&amp;#43;Clin&amp;#43;Oncol&amp;amp;title=Defining&amp;#43;molecular&amp;#43;profiles&amp;#43;of&amp;#43;poor&amp;#43;outcome&amp;#43;in&amp;#43;patients&amp;#43;with&amp;#43;invasive&amp;#43;bladder&amp;#43;cancer&amp;#43;using&amp;#43;oligonucleotide&amp;#43;microarrays&amp;amp;author=M&amp;#43;Sanchez-Carbayo&amp;amp;author=ND&amp;#43;Socci&amp;amp;author=J&amp;#43;Lozano&amp;amp;author=F&amp;#43;Saint&amp;amp;author=C&amp;#43;Cordon-Cardo&amp;amp;volume=24&amp;amp;publication_year=2006&amp;amp;pages=778-789&amp;amp;pmid=16432078&amp;amp;doi=10.1200/JCO.2005.03.2375&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, Segraves R, de Rycke Y, Elvin P, Cassidy A, Spraggon C, et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet. 2006;38:1386–1396. doi: 10.1038/ng1923. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/17099711&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1038%2Fng1923&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Nat&amp;#43;Genet&amp;amp;title=Regional&amp;#43;copy&amp;#43;number-independent&amp;#43;deregulation&amp;#43;of&amp;#43;transcription&amp;#43;in&amp;#43;cancer&amp;amp;author=N&amp;#43;Stransky&amp;amp;author=C&amp;#43;Vallot&amp;amp;author=F&amp;#43;Reyal&amp;amp;author=I&amp;#43;Bernard-Pierrot&amp;amp;author=SG&amp;#43;de&amp;#43;Medina&amp;amp;volume=38&amp;amp;publication_year=2006&amp;amp;pages=1386-1396&amp;amp;pmid=17099711&amp;amp;doi=10.1038/ng1923&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Yu G, Wang LG, Han Y, He QY. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–287. doi: 10.1089/omi.2011.0118. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3339379/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/22455463&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1089%2Fomi.2011.0118&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=OMICS&amp;amp;title=clusterProfiler:&amp;#43;An&amp;#43;R&amp;#43;package&amp;#43;for&amp;#43;comparing&amp;#43;biological&amp;#43;themes&amp;#43;among&amp;#43;gene&amp;#43;clusters&amp;amp;author=G&amp;#43;Yu&amp;amp;author=LG&amp;#43;Wang&amp;amp;author=Y&amp;#43;Han&amp;amp;author=QY&amp;#43;He&amp;amp;volume=16&amp;amp;publication_year=2012&amp;amp;pages=284-287&amp;amp;pmid=22455463&amp;amp;doi=10.1089/omi.2011.0118&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Yu G, He QY. ReactomePA: An R/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst. 2016;12:477–479. doi: 10.1039/C5MB00663E. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/26661513&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1039%2FC5MB00663E&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Mol&amp;#43;Biosyst&amp;amp;title=ReactomePA:&amp;#43;An&amp;#43;R/Bioconductor&amp;#43;package&amp;#43;for&amp;#43;reactome&amp;#43;pathway&amp;#43;analysis&amp;#43;and&amp;#43;visualization&amp;amp;author=G&amp;#43;Yu&amp;amp;author=QY&amp;#43;He&amp;amp;volume=12&amp;amp;publication_year=2016&amp;amp;pages=477-479&amp;amp;pmid=26661513&amp;amp;doi=10.1039/C5MB00663E&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Sjödahl G, Eriksson P, Liedberg F, Höglund M. Molecular classification of urothelial carcinoma: Global mRNA classification versus tumour-cell phenotype classification. J Pathology. 2017;242:113–125. doi: 10.1002/path.4886. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413843/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/28195647&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1002%2Fpath.4886&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=J&amp;#43;Pathology&amp;amp;title=Molecular&amp;#43;classification&amp;#43;of&amp;#43;urothelial&amp;#43;carcinoma:&amp;#43;Global&amp;#43;mRNA&amp;#43;classification&amp;#43;versus&amp;#43;tumour-cell&amp;#43;phenotype&amp;#43;classification&amp;amp;author=G&amp;#43;Sj%C3%B6dahl&amp;amp;author=P&amp;#43;Eriksson&amp;amp;author=F&amp;#43;Liedberg&amp;amp;author=M&amp;#43;H%C3%B6glund&amp;amp;volume=242&amp;amp;publication_year=2017&amp;amp;pages=113-125&amp;amp;doi=10.1002/path.4886&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc National Acad Sci. 2005;102:15545–15550. doi: 10.1073/pnas.0506580102. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1239896/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/16199517&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1073%2Fpnas.0506580102&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Proc&amp;#43;National&amp;#43;Acad&amp;#43;Sci&amp;amp;title=Gene&amp;#43;set&amp;#43;enrichment&amp;#43;analysis:&amp;#43;A&amp;#43;knowledge-based&amp;#43;approach&amp;#43;for&amp;#43;interpreting&amp;#43;genome-wide&amp;#43;expression&amp;#43;profiles&amp;amp;author=A&amp;#43;Subramanian&amp;amp;author=P&amp;#43;Tamayo&amp;amp;author=VK&amp;#43;Mootha&amp;amp;author=S&amp;#43;Mukherjee&amp;amp;author=BL&amp;#43;Ebert&amp;amp;volume=102&amp;amp;publication_year=2005&amp;amp;pages=15545-15550&amp;amp;doi=10.1073/pnas.0506580102&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Villanueva RAM, Chen ZJ. ggplot2: Elegant graphics for data analysis. Meas Interdiscip Res Perspectives. (2nd) 2019;17:160–167. doi: 10.1080/15366367.2019.1565254. [&lt;a href=&#34;https://dx.doi.org/10.1080%2F15366367.2019.1565254&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Meas&amp;#43;Interdiscip&amp;#43;Res&amp;#43;Perspectives&amp;amp;title=ggplot2:&amp;#43;Elegant&amp;#43;graphics&amp;#43;for&amp;#43;data&amp;#43;analysis&amp;amp;author=RAM&amp;#43;Villanueva&amp;amp;author=ZJ&amp;#43;Chen&amp;amp;volume=17&amp;amp;publication_year=2019&amp;amp;pages=160-167&amp;amp;doi=10.1080/15366367.2019.1565254&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Nykopp TK, Batista da Costa J, Mannas M, Black PC. Current clinical trials in non-muscle invasive bladder cancer. Curr Urol Rep. 2018;19:101. doi: 10.1007/s11934-018-0852-6. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/30357541&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1007%2Fs11934-018-0852-6&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Curr&amp;#43;Urol&amp;#43;Rep&amp;amp;title=Current&amp;#43;clinical&amp;#43;trials&amp;#43;in&amp;#43;non-muscle&amp;#43;invasive&amp;#43;bladder&amp;#43;cancer&amp;amp;author=TK&amp;#43;Nykopp&amp;amp;author=J&amp;#43;Batista&amp;#43;da&amp;#43;Costa&amp;amp;author=M&amp;#43;Mannas&amp;amp;author=PC&amp;#43;Black&amp;amp;volume=19&amp;amp;publication_year=2018&amp;amp;pages=101&amp;amp;pmid=30357541&amp;amp;doi=10.1007/s11934-018-0852-6&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–249. doi: 10.1016/S0140-6736(09)60491-8. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/19520422&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2FS0140-6736%2809%2960491-8&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Lancet&amp;amp;title=Bladder&amp;#43;cancer&amp;amp;author=DS&amp;#43;Kaufman&amp;amp;author=WU&amp;#43;Shipley&amp;amp;author=AS&amp;#43;Feldman&amp;amp;volume=374&amp;amp;publication_year=2009&amp;amp;pages=239-249&amp;amp;pmid=19520422&amp;amp;doi=10.1016/S0140-6736%2809%2960491-8&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Heijden AGvd, Witjes JA. Recurrence, progression, and follow-up in non-muscle-invasive bladder cancer. Eur Urol Suppl. 2009;8:556–562. doi: 10.1016/j.eursup.2009.06.010. [&lt;a href=&#34;https://dx.doi.org/10.1016%2Fj.eursup.2009.06.010&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Eur&amp;#43;Urol&amp;#43;Suppl&amp;amp;title=Recurrence,&amp;#43;progression,&amp;#43;and&amp;#43;follow-up&amp;#43;in&amp;#43;non-muscle-invasive&amp;#43;bladder&amp;#43;cancer&amp;amp;author=AGvd&amp;#43;Heijden&amp;amp;author=JA&amp;#43;Witjes&amp;amp;volume=8&amp;amp;publication_year=2009&amp;amp;pages=556-562&amp;amp;doi=10.1016/j.eursup.2009.06.010&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Wang H, Isaji T, Satoh M, Li D, Arai Y, Gu J. Antitumor effects of exogenous ganglioside GM3 on bladder cancer in an orthotopic cancer model. Urology. 2012;81:210.e211–215. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/23102779&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Urology&amp;amp;title=Antitumor&amp;#43;effects&amp;#43;of&amp;#43;exogenous&amp;#43;ganglioside&amp;#43;GM3&amp;#43;on&amp;#43;bladder&amp;#43;cancer&amp;#43;in&amp;#43;an&amp;#43;orthotopic&amp;#43;cancer&amp;#43;model&amp;amp;author=H&amp;#43;Wang&amp;amp;author=T&amp;#43;Isaji&amp;amp;author=M&amp;#43;Satoh&amp;amp;author=D&amp;#43;Li&amp;amp;author=Y&amp;#43;Arai&amp;amp;volume=81&amp;amp;publication_year=2012&amp;amp;pages=210.e211-215&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Li Q, Sun M, Yu M, Fu Q, Jiang H, Yu G, Li G. Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker. Glycoconjugate J. 2019;36:419–428. doi: 10.1007/s10719-019-09885-z. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/31297734&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1007%2Fs10719-019-09885-z&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Glycoconjugate&amp;#43;J&amp;amp;title=Gangliosides&amp;#43;profiling&amp;#43;in&amp;#43;serum&amp;#43;of&amp;#43;breast&amp;#43;cancer&amp;#43;patient:&amp;#43;GM3&amp;#43;as&amp;#43;a&amp;#43;potential&amp;#43;diagnostic&amp;#43;biomarker&amp;amp;author=Q&amp;#43;Li&amp;amp;author=M&amp;#43;Sun&amp;amp;author=M&amp;#43;Yu&amp;amp;author=Q&amp;#43;Fu&amp;amp;author=H&amp;#43;Jiang&amp;amp;volume=36&amp;amp;publication_year=2019&amp;amp;pages=419-428&amp;amp;doi=10.1007/s10719-019-09885-z&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, Vázquez AM, Fainboim L. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in High-Risk and metastatic breast cancer patients. J Immunother. 2006;29:215–223. doi: 10.1097/01.cji.0000188502.11348.34. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/16531822&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1097%2F01.cji.0000188502.11348.34&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=J&amp;#43;Immunother&amp;amp;title=Cellular&amp;#43;and&amp;#43;humoral&amp;#43;immune&amp;#43;response&amp;#43;to&amp;#43;N-Glycolyl-GM3&amp;#43;elicited&amp;#43;by&amp;#43;prolonged&amp;#43;immunotherapy&amp;#43;with&amp;#43;an&amp;#43;anti-idiotypic&amp;#43;vaccine&amp;#43;in&amp;#43;High-Risk&amp;#43;and&amp;#43;metastatic&amp;#43;breast&amp;#43;cancer&amp;#43;patients&amp;amp;author=MD&amp;#43;Guthmann&amp;amp;author=MA&amp;#43;Castro&amp;amp;author=G&amp;#43;Cinat&amp;amp;author=C&amp;#43;Venier&amp;amp;author=L&amp;#43;Koliren&amp;amp;volume=29&amp;amp;publication_year=2006&amp;amp;pages=215-223&amp;amp;pmid=16531822&amp;amp;doi=10.1097/01.cji.0000188502.11348.34&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Cai H, Zhou H, Miao Y, Li N, Zhao L, Jia L. MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5. Lab Invest. 2017;97:530–542. doi: 10.1038/labinvest.2017.12. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/28218742&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1038%2Flabinvest.2017.12&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Lab&amp;#43;Invest&amp;amp;title=MiRNA&amp;#43;expression&amp;#43;profiles&amp;#43;reveal&amp;#43;the&amp;#43;involvement&amp;#43;of&amp;#43;miR-26a,&amp;#43;miR-548l&amp;#43;and&amp;#43;miR-34a&amp;#43;in&amp;#43;hepatocellular&amp;#43;carcinoma&amp;#43;progression&amp;#43;through&amp;#43;regulation&amp;#43;of&amp;#43;ST3GAL5&amp;amp;author=H&amp;#43;Cai&amp;amp;author=H&amp;#43;Zhou&amp;amp;author=Y&amp;#43;Miao&amp;amp;author=N&amp;#43;Li&amp;amp;author=L&amp;#43;Zhao&amp;amp;volume=97&amp;amp;publication_year=2017&amp;amp;pages=530-542&amp;amp;pmid=28218742&amp;amp;doi=10.1038/labinvest.2017.12&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Kawamura S, Ohyama C, Watanabe R, Satoh M, Saito S, Hoshi S, Gasa S, Orikasa S. Glycolipid composition in bladder tumor: A crucial role of GM3 ganglioside in tumor invasion. Int J Cancer. 2001;94:343–347. doi: 10.1002/ijc.1482. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/11745412&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1002%2Fijc.1482&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Int&amp;#43;J&amp;#43;Cancer&amp;amp;title=Glycolipid&amp;#43;composition&amp;#43;in&amp;#43;bladder&amp;#43;tumor:&amp;#43;A&amp;#43;crucial&amp;#43;role&amp;#43;of&amp;#43;GM3&amp;#43;ganglioside&amp;#43;in&amp;#43;tumor&amp;#43;invasion&amp;amp;author=S&amp;#43;Kawamura&amp;amp;author=C&amp;#43;Ohyama&amp;amp;author=R&amp;#43;Watanabe&amp;amp;author=M&amp;#43;Satoh&amp;amp;author=S&amp;#43;Saito&amp;amp;volume=94&amp;amp;publication_year=2001&amp;amp;pages=343-347&amp;amp;pmid=11745412&amp;amp;doi=10.1002/ijc.1482&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Chung TW, Choi HJ, Kim SJ, Kwak CH, Song KH, Jin UH, Chang YC, Chang HW, Lee YC, Ha KT, Kim CH. The ganglioside GM3 is associated with cisplatin-induced apoptosis in human colon cancer cells. PLoS One. 2014;9:e92786. doi: 10.1371/journal.pone.0092786. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020741/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/24829158&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1371%2Fjournal.pone.0092786&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=PLoS&amp;#43;One&amp;amp;title=The&amp;#43;ganglioside&amp;#43;GM3&amp;#43;is&amp;#43;associated&amp;#43;with&amp;#43;cisplatin-induced&amp;#43;apoptosis&amp;#43;in&amp;#43;human&amp;#43;colon&amp;#43;cancer&amp;#43;cells&amp;amp;author=TW&amp;#43;Chung&amp;amp;author=HJ&amp;#43;Choi&amp;amp;author=SJ&amp;#43;Kim&amp;amp;author=CH&amp;#43;Kwak&amp;amp;author=KH&amp;#43;Song&amp;amp;volume=9&amp;amp;publication_year=2014&amp;amp;pages=e92786&amp;amp;pmid=24829158&amp;amp;doi=10.1371/journal.pone.0092786&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Massagué J. TGFβ in Cancer. Cell. 2008;134:215–230. doi: 10.1016/j.cell.2008.07.001. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512574/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/18662538&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2Fj.cell.2008.07.001&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Cell&amp;amp;title=TGF%CE%B2&amp;#43;in&amp;#43;Cancer&amp;amp;author=J&amp;#43;Massagu%C3%A9&amp;amp;volume=134&amp;amp;publication_year=2008&amp;amp;pages=215-230&amp;amp;pmid=18662538&amp;amp;doi=10.1016/j.cell.2008.07.001&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Colak S, Ten Dijke P. Targeting TGF-β signaling in cancer. Trends Cancer. 2017;3:56–71. doi: 10.1016/j.trecan.2016.11.008. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/28718426&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2Fj.trecan.2016.11.008&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Trends&amp;#43;Cancer&amp;amp;title=Targeting&amp;#43;TGF-%CE%B2&amp;#43;signaling&amp;#43;in&amp;#43;cancer&amp;amp;author=S&amp;#43;Colak&amp;amp;author=P&amp;#43;Ten&amp;#43;Dijke&amp;amp;volume=3&amp;amp;publication_year=2017&amp;amp;pages=56-71&amp;amp;pmid=28718426&amp;amp;doi=10.1016/j.trecan.2016.11.008&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Newman AC, Maddocks ODK. One-carbon metabolism in cancer. Brit J Cancer. 2017;116:1499–1504. doi: 10.1038/bjc.2017.118. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518849/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/28472819&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1038%2Fbjc.2017.118&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Brit&amp;#43;J&amp;#43;Cancer&amp;amp;title=One-carbon&amp;#43;metabolism&amp;#43;in&amp;#43;cancer&amp;amp;author=AC&amp;#43;Newman&amp;amp;author=ODK&amp;#43;Maddocks&amp;amp;volume=116&amp;amp;publication_year=2017&amp;amp;pages=1499-1504&amp;amp;pmid=28472819&amp;amp;doi=10.1038/bjc.2017.118&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Moore LE, Malats N, Rothman N, Real FX, Kogevinas M, Karami S, García-Closas R, Silverman D, Chanock S, Welch R, et al. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. Int J Cancer. 2007;120:2452–2458. doi: 10.1002/ijc.22565. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/17311259&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1002%2Fijc.22565&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Int&amp;#43;J&amp;#43;Cancer&amp;amp;title=Polymorphisms&amp;#43;in&amp;#43;one-carbon&amp;#43;metabolism&amp;#43;and&amp;#43;trans-sulfuration&amp;#43;pathway&amp;#43;genes&amp;#43;and&amp;#43;susceptibility&amp;#43;to&amp;#43;bladder&amp;#43;cancer&amp;amp;author=LE&amp;#43;Moore&amp;amp;author=N&amp;#43;Malats&amp;amp;author=N&amp;#43;Rothman&amp;amp;author=FX&amp;#43;Real&amp;amp;author=M&amp;#43;Kogevinas&amp;amp;volume=120&amp;amp;publication_year=2007&amp;amp;pages=2452-2458&amp;amp;pmid=17311259&amp;amp;doi=10.1002/ijc.22565&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Li X, Che K, Wang L, Zhang T, Wang G, Pang Z, Shen H, Du J. Subcellular localization of β-arrestin1 and its prognostic value in lung adenocarcinoma. Medicine. 2017;96:e8450. doi: 10.1097/MD.0000000000008450. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690724/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/29137031&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1097%2FMD.0000000000008450&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Medicine&amp;amp;title=Subcellular&amp;#43;localization&amp;#43;of&amp;#43;%CE%B2-arrestin1&amp;#43;and&amp;#43;its&amp;#43;prognostic&amp;#43;value&amp;#43;in&amp;#43;lung&amp;#43;adenocarcinoma&amp;amp;author=X&amp;#43;Li&amp;amp;author=K&amp;#43;Che&amp;amp;author=L&amp;#43;Wang&amp;amp;author=T&amp;#43;Zhang&amp;amp;author=G&amp;#43;Wang&amp;amp;volume=96&amp;amp;publication_year=2017&amp;amp;pages=e8450&amp;amp;pmid=29137031&amp;amp;doi=10.1097/MD.0000000000008450&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Liu J, Wang H, Huang C, Qian H. Subcellular localization of MTA proteins in normal and cancer cells. Cancer Metastasis Rev. 2014;33:843–856. doi: 10.1007/s10555-014-9511-7. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/25398252&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1007%2Fs10555-014-9511-7&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Cancer&amp;#43;Metastasis&amp;#43;Rev&amp;amp;title=Subcellular&amp;#43;localization&amp;#43;of&amp;#43;MTA&amp;#43;proteins&amp;#43;in&amp;#43;normal&amp;#43;and&amp;#43;cancer&amp;#43;cells&amp;amp;author=J&amp;#43;Liu&amp;amp;author=H&amp;#43;Wang&amp;amp;author=C&amp;#43;Huang&amp;amp;author=H&amp;#43;Qian&amp;amp;volume=33&amp;amp;publication_year=2014&amp;amp;pages=843-856&amp;amp;pmid=25398252&amp;amp;doi=10.1007/s10555-014-9511-7&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Kim HJ, Lee SY, Kim CY, Kim YH, Ju W, Kim SC. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells. Oncotarget. 2017;8:6608–6622. doi: 10.18632/oncotarget.14245. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351656/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/28036259&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.18632%2Foncotarget.14245&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;amp;title=Subcellular&amp;#43;localization&amp;#43;of&amp;#43;FOXO3a&amp;#43;as&amp;#43;a&amp;#43;potential&amp;#43;biomarker&amp;#43;of&amp;#43;response&amp;#43;to&amp;#43;combined&amp;#43;treatment&amp;#43;with&amp;#43;inhibitors&amp;#43;of&amp;#43;PI3K&amp;#43;and&amp;#43;autophagy&amp;#43;in&amp;#43;PIK3CA-mutant&amp;#43;cancer&amp;#43;cells&amp;amp;author=HJ&amp;#43;Kim&amp;amp;author=SY&amp;#43;Lee&amp;amp;author=CY&amp;#43;Kim&amp;amp;author=YH&amp;#43;Kim&amp;amp;author=W&amp;#43;Ju&amp;amp;volume=8&amp;amp;publication_year=2017&amp;amp;pages=6608-6622&amp;amp;pmid=28036259&amp;amp;doi=10.18632/oncotarget.14245&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Boudhraa Z, Bouchon B, Viallard C, D&amp;rsquo;Incan M, Degoul F. Annexin A1 localization and its relevance to cancer. Clin Sci (Lond) 2016;130:205–220. doi: 10.1042/CS20150415. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/26769657&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1042%2FCS20150415&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Clin&amp;#43;Sci&amp;#43;%28Lond%29&amp;amp;title=Annexin&amp;#43;A1&amp;#43;localization&amp;#43;and&amp;#43;its&amp;#43;relevance&amp;#43;to&amp;#43;cancer&amp;amp;author=Z&amp;#43;Boudhraa&amp;amp;author=B&amp;#43;Bouchon&amp;amp;author=C&amp;#43;Viallard&amp;amp;author=M&amp;#43;D%27Incan&amp;amp;author=F&amp;#43;Degoul&amp;amp;volume=130&amp;amp;publication_year=2016&amp;amp;pages=205-220&amp;amp;pmid=26769657&amp;amp;doi=10.1042/CS20150415&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol. 2019;40:228–242. doi: 10.1016/j.it.2019.01.006. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/30777721&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2Fj.it.2019.01.006&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Trends&amp;#43;Immunol&amp;amp;title=Neutrophil&amp;#43;degranulation,&amp;#43;plasticity,&amp;#43;and&amp;#43;cancer&amp;#43;metastasis&amp;amp;author=F&amp;#43;Mollinedo&amp;amp;volume=40&amp;amp;publication_year=2019&amp;amp;pages=228-242&amp;amp;pmid=30777721&amp;amp;doi=10.1016/j.it.2019.01.006&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Hanahan D, Weinberg Robert A. Hallmarks of cancer: The next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/21376230&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2Fj.cell.2011.02.013&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Cell&amp;amp;title=Hallmarks&amp;#43;of&amp;#43;cancer:&amp;#43;The&amp;#43;next&amp;#43;generation&amp;amp;author=D&amp;#43;Hanahan&amp;amp;author=A&amp;#43;Weinberg&amp;#43;Robert&amp;amp;volume=144&amp;amp;publication_year=2011&amp;amp;pages=646-674&amp;amp;pmid=21376230&amp;amp;doi=10.1016/j.cell.2011.02.013&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Takeuchi H, Tanaka M, Tanaka A, Tsunemi A, Yamamoto H. Predominance of M2-polarized macrophages in bladder cancer affects angiogenesis, tumor grade and invasiveness. Oncol Lett. 2016;11:3403–3408. doi: 10.3892/ol.2016.4392. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841030/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/27123124&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.3892%2Fol.2016.4392&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Oncol&amp;#43;Lett&amp;amp;title=Predominance&amp;#43;of&amp;#43;M2-polarized&amp;#43;macrophages&amp;#43;in&amp;#43;bladder&amp;#43;cancer&amp;#43;affects&amp;#43;angiogenesis,&amp;#43;tumor&amp;#43;grade&amp;#43;and&amp;#43;invasiveness&amp;amp;author=H&amp;#43;Takeuchi&amp;amp;author=M&amp;#43;Tanaka&amp;amp;author=A&amp;#43;Tanaka&amp;amp;author=A&amp;#43;Tsunemi&amp;amp;author=H&amp;#43;Yamamoto&amp;amp;volume=11&amp;amp;publication_year=2016&amp;amp;pages=3403-3408&amp;amp;pmid=27123124&amp;amp;doi=10.3892/ol.2016.4392&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: Neutral no more. Nat Rev Cancer. 2016;16:431–446. doi: 10.1038/nrc.2016.52. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/27282249&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1038%2Fnrc.2016.52&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Nat&amp;#43;Rev&amp;#43;Cancer&amp;amp;title=Neutrophils&amp;#43;in&amp;#43;cancer:&amp;#43;Neutral&amp;#43;no&amp;#43;more&amp;amp;author=SB&amp;#43;Coffelt&amp;amp;author=MD&amp;#43;Wellenstein&amp;amp;author=KE&amp;#43;de&amp;#43;Visser&amp;amp;volume=16&amp;amp;publication_year=2016&amp;amp;pages=431-446&amp;amp;pmid=27282249&amp;amp;doi=10.1038/nrc.2016.52&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Kent A, Blander JM. Nod-like receptors: Key molecular switches in the conundrum of cancer. Front Immunol. 2014;5:185. doi: 10.3389/fimmu.2014.00185. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005929/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/24795727&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.3389%2Ffimmu.2014.00185&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Front&amp;#43;Immunol&amp;amp;title=Nod-like&amp;#43;receptors:&amp;#43;Key&amp;#43;molecular&amp;#43;switches&amp;#43;in&amp;#43;the&amp;#43;conundrum&amp;#43;of&amp;#43;cancer&amp;amp;author=A&amp;#43;Kent&amp;amp;author=JM&amp;#43;Blander&amp;amp;volume=5&amp;amp;publication_year=2014&amp;amp;pages=185&amp;amp;pmid=24795727&amp;amp;doi=10.3389/fimmu.2014.00185&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Saxena M, Yeretssian G. NOD-like receptors: Master regulators of inflammation and cancer. Front Immunol. 2014;5:327. doi: 10.3389/fimmu.2014.00327. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095565/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/25071785&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.3389%2Ffimmu.2014.00327&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Front&amp;#43;Immunol&amp;amp;title=NOD-like&amp;#43;receptors:&amp;#43;Master&amp;#43;regulators&amp;#43;of&amp;#43;inflammation&amp;#43;and&amp;#43;cancer&amp;amp;author=M&amp;#43;Saxena&amp;amp;author=G&amp;#43;Yeretssian&amp;amp;volume=5&amp;amp;publication_year=2014&amp;amp;pages=327&amp;amp;pmid=25071785&amp;amp;doi=10.3389/fimmu.2014.00327&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Ozaki K, Leonard WJ. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem. 2002;277:29355–29358. doi: 10.1074/jbc.R200003200. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/12072446&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1074%2Fjbc.R200003200&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=J&amp;#43;Biol&amp;#43;Chem&amp;amp;title=Cytokine&amp;#43;and&amp;#43;cytokine&amp;#43;receptor&amp;#43;pleiotropy&amp;#43;and&amp;#43;redundancy&amp;amp;author=K&amp;#43;Ozaki&amp;amp;author=WJ&amp;#43;Leonard&amp;amp;volume=277&amp;amp;publication_year=2002&amp;amp;pages=29355-29358&amp;amp;pmid=12072446&amp;amp;doi=10.1074/jbc.R200003200&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Pencik J, Pham HTT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F, Kenner L. JAK-STAT signaling in cancer: From cytokines to non-coding genome. Cytokine. 2016;87:26–36. doi: 10.1016/j.cyto.2016.06.017. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059362/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/27349799&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.1016%2Fj.cyto.2016.06.017&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Cytokine&amp;amp;title=JAK-STAT&amp;#43;signaling&amp;#43;in&amp;#43;cancer:&amp;#43;From&amp;#43;cytokines&amp;#43;to&amp;#43;non-coding&amp;#43;genome&amp;amp;author=J&amp;#43;Pencik&amp;amp;author=HTT&amp;#43;Pham&amp;amp;author=J&amp;#43;Schmoellerl&amp;amp;author=T&amp;#43;Javaheri&amp;amp;author=M&amp;#43;Schlederer&amp;amp;volume=87&amp;amp;publication_year=2016&amp;amp;pages=26-36&amp;amp;pmid=27349799&amp;amp;doi=10.1016/j.cyto.2016.06.017&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;li&gt;Trivedi S, Starz-Gaiano M. Drosophila Jak/STAT signaling: Regulation and relevance in human cancer and metastasis. Int J Mol Sci. 2018;19:4056. doi: 10.3390/ijms19124056. [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320922/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PMC free article&lt;/a&gt;] [&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/30558204&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;PubMed&lt;/a&gt;] [&lt;a href=&#34;https://dx.doi.org/10.3390%2Fijms19124056&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;CrossRef&lt;/a&gt;] [&lt;a href=&#34;https://scholar.google.com/scholar_lookup?journal=Int&amp;#43;J&amp;#43;Mol&amp;#43;Sci&amp;amp;title=Drosophila&amp;#43;Jak/STAT&amp;#43;signaling:&amp;#43;Regulation&amp;#43;and&amp;#43;relevance&amp;#43;in&amp;#43;human&amp;#43;cancer&amp;#43;and&amp;#43;metastasis&amp;amp;author=S&amp;#43;Trivedi&amp;amp;author=M&amp;#43;Starz-Gaiano&amp;amp;volume=19&amp;amp;publication_year=2018&amp;amp;pages=4056&amp;amp;doi=10.3390/ijms19124056&amp;amp;&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Google Scholar&lt;/a&gt;]&lt;/li&gt;
&lt;/ol&gt;
</description>
    </item>
    
    <item>
      <title>Construction of recombinant lentiviral vector containing human stem cell leukemia gene and its expression in interstitial cells of cajal</title>
      <link>https://swcyo.netlify.app/publication/lichen1/</link>
      <pubDate>Wed, 25 Mar 2020 00:00:00 +0000</pubDate>
      <guid>https://swcyo.netlify.app/publication/lichen1/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Keywords:&lt;/strong&gt; &lt;a href=&#34;https://www.degruyter.com/search?query=keywordValues%3A%28%22diabetic%20cystopathy%22%29%20AND%20journalKey%3A%28%22BIOL%22%29&amp;amp;documentTypeFacet=article&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;diabetic cystopathy&lt;/a&gt;; &lt;a href=&#34;https://www.degruyter.com/search?query=keywordValues%3A%28%22stem%20cell%20leukemia%20gene%22%29%20AND%20journalKey%3A%28%22BIOL%22%29&amp;amp;documentTypeFacet=article&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;stem cell leukemia gene&lt;/a&gt;; &lt;a href=&#34;https://www.degruyter.com/search?query=keywordValues%3A%28%22lentiviral%20vectors%22%29%20AND%20journalKey%3A%28%22BIOL%22%29&amp;amp;documentTypeFacet=article&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;lentiviral vectors&lt;/a&gt;; &lt;a href=&#34;https://www.degruyter.com/search?query=keywordValues%3A%28%22transfection%22%29%20AND%20journalKey%3A%28%22BIOL%22%29&amp;amp;documentTypeFacet=article&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;transfection&lt;/a&gt;; &lt;a href=&#34;https://www.degruyter.com/search?query=keywordValues%3A%28%22interstitial%20cells%20of%20Cajal%22%29%20AND%20journalKey%3A%28%22BIOL%22%29&amp;amp;documentTypeFacet=article&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;interstitial cells of Cajal&lt;/a&gt;&lt;/p&gt;
&lt;h2 id=&#34;1-introduction&#34;&gt;1 Introduction&lt;/h2&gt;
&lt;p&gt;Diabetic cystopathy (DCP) is one of the most common complications of late diabetes, and the incidence in diabetes patients is 19% ~ 84% [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_001_w2aab3b7c51b1b6b1ab2b2b1Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;1&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_002_w2aab3b7c51b1b6b1ab2b2b2Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;2&lt;/a&gt;]. In late DCP, urinary tract infection and nephritis may occur and may develop into uremia [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_003_w2aab3b7c51b1b6b1ab2b2b3Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;3&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_004_w2aab3b7c51b1b6b1ab2b2b4Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;4&lt;/a&gt;]. Many factors including decrease of nerve growth factor (NGF) levels, formation of oxidative free radicals, abnormal glucose metabolism, decrease of prostaglandin E2 (PGE2) levels, increase of mitochondrial reactive oxygen species (ROS), and reduction of the supply of blood vessels can lead to the occurrence of DCP [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_005_w2aab3b7c51b1b6b1ab2b2b5Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;5&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_006_w2aab3b7c51b1b6b1ab2b2b6Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;6&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_007_w2aab3b7c51b1b6b1ab2b2b7Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;7&lt;/a&gt;]. However, the exact pathogenesis is still unclear. Recent studies have discovered a kind of specific cell type similar to the morphology of interstitial cells of Cajal (ICC) in the detrusor of humans, guinea pigs, and many other animals which is called bladder ICC [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_008_w2aab3b7c51b1b6b1ab2b2b8Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;8&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_009_w2aab3b7c51b1b6b1ab2b2b9Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;9&lt;/a&gt;]. Studies confirm that spontaneous detrusor contractions completely regulated by ICCs occur, and thus ICCs may be possible bladder pacemaker cells [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_010_w2aab3b7c51b1b6b1ab2b2c10Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;10&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_011_w2aab3b7c51b1b6b1ab2b2c11Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;11&lt;/a&gt;]. A tyrosine kinase receptor c-kit is present on the surface and cytoplasm of ICC cells and is considered to be a specific marker of ICC [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_012_w2aab3b7c51b1b6b1ab2b2c12Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;12&lt;/a&gt;]. The SCL gene is an important regulatory gene upstream of c-kit, and it mainly acts on the gene promoter of c-kit, thereby regulating c-kit expression [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_013_w2aab3b7c51b1b6b1ab2b2c13Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;13&lt;/a&gt;]. For DCP patients, ICCs continue to shrink or disappear due to the induction of hyperglycemia, which can damage the transmission functions of the stem cell factor (SCF)/growth factor receptor tyrosine kinase (c-kit) signaling pathway [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_014_w2aab3b7c51b1b6b1ab2b2c14Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;14&lt;/a&gt;], lead to the reduction of bladder sensation, increase urine storage capacity, decrease detrusor contractility during urination, increase bladder residual urine and other discomforts, and result in bladder function becoming completely paralyzed or even failing [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_015_w2aab3b7c51b1b6b1ab2b2c15Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;15&lt;/a&gt;].&lt;/p&gt;
&lt;p&gt;There are two key receptors on ICCs, the specific protein receptor c-kit and its ligand stem cell factor (SCF). The specific binding of c-kit and SCF can start the SCF / c-kit signaling pathway [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_016_w2aab3b7c51b1b6b1ab2b2c16Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;16&lt;/a&gt;]. Research has shown that the stem cell leukemia (SCL) gene is an upstream necessary regulator of c-kit which can increase the expression of c-kit and then promote the recovery of the ICC phenotype and function in DCP [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_017_w2aab3b7c51b1b6b1ab2b2c17Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;17&lt;/a&gt;]. Therefore, the SCF/c-kit signaling pathway plays a key role in promoting ICC function reversal, which can guide the clinical treatment of DCP.&lt;/p&gt;
&lt;p&gt;Recombinant lentiviral vectors containing human SCL gene can be used to infect ICC cells with morphological and functional damage to increase the number and promote the functional recovery of ICCs. In this study, recombinant lentiviral vectors containing the SCL gene were constructed using genetic engineering techniques and used to transfect &lt;em&gt;in vitro&lt;/em&gt; cultured ICCs. The transfection efficiency and expression of the SCL gene were investigated. Our findings may provide new ideas for the further use of lentiviral vectors containing the human SCL gene in transfection experiments &lt;em&gt;in vivo&lt;/em&gt; and DCP treatment.&lt;/p&gt;
&lt;h2 id=&#34;2-materials-and-methods&#34;&gt;2 Materials and Methods&lt;/h2&gt;
&lt;h3 id=&#34;21-experimental-animals&#34;&gt;2.1 Experimental animals&lt;/h3&gt;
&lt;p&gt;A total of 40 guinea pigs of either gender was used for the study. Their ages were 6-12 months and weight was 250-400 g. All guinea pigs were purchased from the Animal Experimental Center of Xinjiang Medical University.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Ethical approval&lt;/strong&gt;: The research related to animals use has been complied with all the relevant national regulations and institutional policies for the care and use of animals. All animal experiments were conducted according to the ethical guidelines of the First Affiliated Hospital of Shihezi University.&lt;/p&gt;
&lt;h3 id=&#34;22-reagents&#34;&gt;2.2 Reagents&lt;/h3&gt;
&lt;p&gt;Competent &lt;em&gt;E. coli&lt;/em&gt; DH5α, 293T cells, and GV287-EGFP vector were purchased from Genechem (Shanghai) Co. (Shanghai, China). DMEM medium, fetal bovine serum (FBS), and Lipofectamine 2000 transfection kit were purchased from Invitrogen Co. (Carlsbad, CA, US). RT-PCR kit was purchased from Fermentas Co. (Waltham, MA, US).&lt;/p&gt;
&lt;h3 id=&#34;23-construction-and-identification-of-lentiviral-vectors-containing-the-human-scl-gene&#34;&gt;2.3 Construction and identification of lentiviral vectors containing the human SCL gene&lt;/h3&gt;
&lt;p&gt;The recombinant lentiviral plasmid containing the human SCL gene was constructed by the assistance of Genechem (Shanghai) Co. (Shanghai, China). Briefly, the human SCL gene was amplified by PCR. The primers were as follows: upstream 5’-GAGGATCCCCGGGTACCGGTCGCCACCAT-GACCGAGCGGCCGCCGAG-3’ and downstream 5’-TCAC-CATGGTGGCGACCGGCCGAGGGCCGGCTCCATC-3’.&lt;/p&gt;
&lt;p&gt;The primers were synthesized by Genechem (Shanghai) Co. The PCR procedure was as follows: denaturing at 94oC for 5 min, 30 cycles of denaturation at 94oC for 30 s, annealing at 55oC for 30 s, extension at 72oC for 2 min, and a final extension at 72oC for 10 min. The PCR product was verified by agarose gel electrophoresis. Then, the PCR product was purified and inserted into the GV287-EGFP vector by In-Fusion converting enzyme (QIAGEN Co., Valencia, CA, USA) to construct recombinant plasmid GV287-EGFP/SCL. The correctly constructed recombinant plasmid GV287-EGFP/SCL was identified by sequencing.&lt;/p&gt;
&lt;h3 id=&#34;24-packaging-of-lentiviral-vector-and-detection-of-virus-titer&#34;&gt;2.4 Packaging of lentiviral vector and detection of virus titer&lt;/h3&gt;
&lt;p&gt;In a 1.5 mL sterile EP tube, 1.5 μg of packaging helper plasmids (Helper 1.0 and Helper 2.0, Genechem Co. Shanghai, China), 0.5 μg of expression plasmid, and 250 μL serum-free medium were added, mixed, and incubated at room temperature for 5 min. At the same time, 9 μL of liposomes was mixed with 250 μL serum-free medium and incubated at room temperature for 5 min. Then, the above DNA solution and liposome suspension were mixed and incubated at room temperature for 20 min. The 293T cell line was used as the packaging cell. The mixture of DNA and liposome was put into a 6-well plate and supplied with 1 mL complete medium. 293T cell suspension (1 ml) was put into the 6-well plate and incubated at 37oC in an atmosphere with CO2 for 48-72 h. After that, the cells were centrifuged at 3000 r/min for 20 minutes, and the precipitate was filtered. The lentivirus stock solution was filtered with PVDF membrane. Virus-containing medium were grouped by 1: 100 dilutions and divided into standard solution and test solution. Both solutions were used for transfecting 293T cells simultaneously, and the virus titer was calculated by a fluorescent labeling method [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_008_w2aab3b7c51b1b6b1ab2b2b8Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;8&lt;/a&gt;].&lt;/p&gt;
&lt;h3 id=&#34;25-in-vitro-culture-of-bladder-iccs-of-guinea-pigs&#34;&gt;2.5 &lt;em&gt;In vitro&lt;/em&gt; culture of bladder ICCs of guinea pigs&lt;/h3&gt;
&lt;p&gt;Four healthy guinea pigs were randomly selected and sacrificed by cervical dislocation. Their bladder tissues were removed in a sterile environment and cut into 1 mm3 pieces. The tissue pieces were digested with 1.0 mg/mL trypsin for 15 min at 37oC. DMEM medium (containing 1.0 mg/mL collagenase V, 100 U/mL penicillin, and 100 g/mL streptomycin) was added, and the tissues were further digested for 90 min at 37oC. Then, the digested tissues were filtered and centrifuged at 350 xg for 5 min. The supernatant was discarded, and the pellet was washed with 1% phosphate buffer solution (PBS). It was then centrifuged at 350 xg three times for 5 min each. Single cells were suspended by pipetting and then seeded in a 6-well plate. Low glucose DMEM medium containing 10% FBS and 1% double antibiotics (100 U/mL penicillin and 100 g/mL streptomycin) were added to each well, and the plate was then cultured at 37oC in an incubator. After 24 hours, the cells were observed under an inverted microscope, and the non-adhered smooth muscle cells were removed. The adhered ICCs were transferred to culture dishes and identified by immunofluorescence after 72 hours of incubation.&lt;/p&gt;
&lt;h3 id=&#34;26-immunofluorescence&#34;&gt;2.6 Immunofluorescence&lt;/h3&gt;
&lt;p&gt;In a 6-well plate, a sterile slide was put into each well, and the ICC suspension was dropped on the center of the slide. About 1 mL medium was added to each well, and another 1 mL medium was added after 8 hours of incubation. After 48 hours of incubation, the slides were taken out. The primary (rat anti-mouse c-kit monoclonal antibody) and secondary antibody (FITC-labeled rabbit anti-rat antibody) were diluted with antibody diluent to reach their working concentration 1: 100. The procedure of the immunohistochemical test was as follows: briefly, the slides were incubated in 100% acetone at room temperature for 10 minutes. After washing with 0.01 M PBS three times (5 minutes each time), the endogenous peroxidase was inactivated with 0.03% H2O2 for 20 minutes at room temperature. Then, the slides were blocked with 1% FBS albumin for 30 minutes at room temperature. After blocking, the slides were incubated with primary antibody of rat anti-mouse c-kit monoclonal antibody (1: 100, Merck Millipore Co., Germany) in a wet box for 2 hours at room temperature and then for 48 hours at 4oC. After washing, FITC-labeled secondary antibody (rabbit anti-rat antibody, 1: 100, Sigma Co., St. Louis, MO, USA) was added and incubated in the dark for 60 minutes. Finally, the slides were sealed with cover glass using 50% glycerol and observed under a fluorescence microscope and a laser scanning confocal microscope.&lt;/p&gt;
&lt;h3 id=&#34;27-determination-of-the-optimal-moi-of-the-lentiviral-vector-containing-human-scl-gene-into-iccs&#34;&gt;2.7 Determination of the optimal MOI of the lentiviral vector containing human SCL gene into ICCs&lt;/h3&gt;
&lt;p&gt;According to the manual for lentiviral transfection (provided by Genechem Co.), ICCs were added with 5×108 TU/mL lentiviral vectors containing the SCL gene at different MOIs (0.5, 1.0, 5.0, 10.0, 50.0, and 100.0), and 10 μg/mL polybrene was simultaneously added. After incubation for 8-12 h, the cells were observed under a microscope. After another 48 h incubation, the growth of ICCs was observed under a laser scanning confocal microscope, and the transfection efficiency was calculated [Transfection efficiency = (Number of cells expressing GFP/Total cell number) × 100%] to determine the optimal MOI.&lt;/p&gt;
&lt;h3 id=&#34;28-determination-of-the-optimal-transfection-time-of-the-lentiviral-vector-containing-the-human-scl-gene-into-iccs&#34;&gt;2.8 Determination of the optimal transfection time of the lentiviral vector containing the human SCL gene into ICCs&lt;/h3&gt;
&lt;p&gt;ICCs were seeded in a 96-well plate at a concentration of 3×104~5×104/mL. The ICCs were divided into a normal control group, blank plasmid control group, and lentivirus transfection group using a random number table method. In the normal control group, 1% PBS was added. In the blank plasmid control group, blank lentivirus was added. In the lentivirus transfection group, the lentiviral vector containing human SCL gene was added at the optimal MOI together with 10 μg/mL polybrene. After 24 hours of incubation, the medium was removed, and the cells were washed with 1% PBS twice, and then 1 mL fresh DMEM medium containing 10% FBS was added for further incubation. The cells were observed using the laser scanning microscope at the 2, 3, and 5 d after transfection. A total of 20 continuous perpendicular to the horizontal views (about 0.77 mm2/view, 200 ×) were observed. The optimal transfection time was determined by observing the expression intensity of GFP.&lt;/p&gt;
&lt;h3 id=&#34;29-rt-pcr&#34;&gt;2.9 RT-PCR&lt;/h3&gt;
&lt;p&gt;The total RNA of ICCs was extracted at 2, 3, and 5 d after transfection, and the expression of SCL mRNA was analyzed using RT-PCR. The primers of SCL and GAPDH were as follows:&lt;/p&gt;
&lt;p&gt;SCL: Upstream: 5’-GAGGATCCCCGGTACCGGTCGC-CACCATGCGAGCGGCCGCCGAG-3’; Downstream: 5’-TCAC-CATGGTGGCGACCGACCGGCCGAGGGCCGGCTCCATC-3’.&lt;/p&gt;
&lt;p&gt;GAPDH: Upstream: 5’-ACCACAGTCCATGCCATCAC-3’; Downstream: 5’-TCCACCACCCTGTTGCTGTA-3’.&lt;/p&gt;
&lt;p&gt;The size of SCL is 1036 bp, while that of GADPH is 456 bp. The PCR reaction procedure was as follows: denaturing at 94oC for 5 min, 30 cycles of denaturation at 94oC for 30 s, annealing at 53oC for 30 s, and extension at 72oC for 1 min and a final extension at 72oC for 10 min. The products were detected with agarose gel electrophoresis. Gel imaging and gray intensity analysis were performed using a gel analysis system, and the expression of SCL mRNA in each group of ICCs was detected.&lt;/p&gt;
&lt;h3 id=&#34;210-statistical-analysis&#34;&gt;2.10 Statistical analysis&lt;/h3&gt;
&lt;p&gt;Data analysis was performed with the statistical software SPSS 17.0. The data was expressed as mean ± standard deviation (SD). ANOVA was used for the comparison among groups, and SNK-q test was used for the comparison between two groups. A &lt;em&gt;P&lt;/em&gt;&amp;lt; 0.05 was considered to be statistically significant.&lt;/p&gt;
&lt;h2 id=&#34;3-results&#34;&gt;3 Results&lt;/h2&gt;
&lt;h3 id=&#34;31-separation-culture-and-identification-of-guinea-pig-iccs&#34;&gt;3.1 Separation, culture and identification of guinea pig ICCs&lt;/h3&gt;
&lt;p&gt;To confirm whether the cultured cells were ICCs, c-kit antibody was used to identify the ICCs. After 24 hours of seeding, some spindle cells were observed with both sides and had obvious convex. Their nuclei were large, and there were some black glycogen particles in the cytoplasm. They had regular shapes, and most of them grew adherently (&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_fig_001_w2aab3b7c51b1b6b1ab1b2b2b3Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Figure 1A)&lt;/a&gt;. After incubation for another 72 hours, the above cells were identified by immunofluorescence using the antibody of c-kit, which is an ICC-specific marker. The ICC-specific receptor tyrosine kinase (c-kit) was successfully expressed (&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_fig_001_w2aab3b7c51b1b6b1ab1b2b2b3Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Figure 1B)&lt;/a&gt;. This result verified that the cultured cells were ICCs.&lt;/p&gt;
&lt;p&gt;















&lt;figure  &gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img src=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/asset/graphic/j_biol-2020-0010_fig_001.jpg&#34; alt=&#34;Figure 1 Identification of ICCs after GFP-SCL transfection. (A) After 2 days of incubation, adherent spindle cells with two projections on the two poles were observed under an inverted microscope (200×). (B) Tyrosine kinase (c-kit) receptor positive cells detected by immunofluorescence assays (200×).&#34; loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;h3 id=&#34;figure-1&#34;&gt;Figure 1&lt;/h3&gt;
&lt;p&gt;Identification of ICCs after GFP-SCL transfection. (A) After 2 days of incubation, adherent spindle cells with two projections on the two poles were observed under an inverted microscope (200×). (B) Tyrosine kinase (c-kit) receptor positive cells detected by immunofluorescence assays (200×).&lt;/p&gt;
&lt;h3 id=&#34;32-the-optimal-moi-for-the-lentiviral-transfection-into-iccs&#34;&gt;3.2 The optimal MOI for the lentiviral transfection into ICCs&lt;/h3&gt;
&lt;p&gt;The GV287-SCL recombinant lentivirus vector was successfully constructed. The virus titer was 5 × 108 TU/ mL. To determine the optimal MOI for the lentiviral vector containing the human SCL gene to transfect cells, transfection efficiency of different MOI was measured. After 48 h of transfection, green fluorescence was observed under the laser scanning confocal microscope. As shown in &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_fig_002_w2aab3b7c51b1b6b1ab1b2b3b3Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Figure 2&lt;/a&gt;, when MOI was 0.5, 1.0, 5.0, 10.0, 50.0, and 100.0, the transfection efficiencies were 35.42% ± 0.12%, 58.04% ± 2.28%, 74.47% ± 3.22%, 85.62% ± 0.33%, 90.39% ± 0.67%, 90.77 ± 0.40%, respectively. When MOI ≥ 10.0, the transfection efficiencies all maintained above 85%, and there were statistically significant differences from those at MOI &amp;lt; 10.0 (P &amp;lt; 0.05, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_tab_001_w2aab3b7c51b1b6b1ab1b2b3b4Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Table 1&lt;/a&gt;). When MOI ≤ 10.0, the cell growth was good and had no cell death. When MOI ≥ 50.0, although the transfection efficiencies were high, part of the cells were dead, and the cell activity decreased. Taking into consideration the transfection efficiency and cell activity at each MOI value, the optimal MOI for the lentiviral vector containing the human SCL gene was determined to be 10.0.&lt;/p&gt;
&lt;p&gt;















&lt;figure  &gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img src=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/asset/graphic/j_biol-2020-0010_fig_002.jpg&#34; alt=&#34;Figure 2 ICCs transfected with lentivirus at different MOIs for 48 h observed by an inverted phase contrast microscope (200×). The representative images at different MOI (MOI = 0.5; MOI = 1.0; MOI = 5.0; MOI = 10.0; MOI = 50.0; MOI = 100.0) were shown.&#34; loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;h3 id=&#34;figure-2&#34;&gt;Figure 2&lt;/h3&gt;
&lt;p&gt;ICCs transfected with lentivirus at different MOIs for 48 h observed by an inverted phase contrast microscope (200×). The representative images at different MOI (MOI = 0.5; MOI = 1.0; MOI = 5.0; MOI = 10.0; MOI = 50.0; MOI = 100.0) were shown.&lt;/p&gt;
&lt;p&gt;Table 1Transfection efficiencies of the lentivirus into ICCs at different MOI values (mean &lt;strong&gt;±&lt;/strong&gt; SD, n=4).&lt;/p&gt;
&lt;table&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:left&#34;&gt;MOI&lt;/th&gt;
&lt;th style=&#34;text-align:left&#34;&gt;Transfection efficiency (%)&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;0.5&lt;/td&gt;
&lt;td style=&#34;text-align:left&#34;&gt;35.42 ± 0.12&lt;a href=&#34;&#34;&gt;**[a]**&lt;/a&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;1.0&lt;/td&gt;
&lt;td style=&#34;text-align:left&#34;&gt;58.04 ± 2.28&lt;a href=&#34;&#34;&gt;**[b]**&lt;/a&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;5.0&lt;/td&gt;
&lt;td style=&#34;text-align:left&#34;&gt;74.47± 3.22&lt;a href=&#34;&#34;&gt;**[c]**&lt;/a&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;10.0&lt;/td&gt;
&lt;td style=&#34;text-align:left&#34;&gt;85.62 ± 0.33&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;50.0&lt;/td&gt;
&lt;td style=&#34;text-align:left&#34;&gt;90.39 ± 0.67&lt;a href=&#34;&#34;&gt;**[d]**&lt;/a&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;100.0&lt;/td&gt;
&lt;td style=&#34;text-align:left&#34;&gt;90.77 ± 0.40&lt;a href=&#34;&#34;&gt;**[e]**&lt;/a&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;F value&lt;/td&gt;
&lt;td style=&#34;text-align:left&#34;&gt;326.30&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:left&#34;&gt;P value&lt;/td&gt;
&lt;td style=&#34;text-align:left&#34;&gt;&amp;lt;0.001&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;h2 id=&#34;heading&#34;&gt;&lt;/h2&gt;
&lt;p&gt;Note: MOI, multiplicity of infection&lt;/p&gt;
&lt;h3 id=&#34;33-the-optimal-transfection-time-for-the-lentiviral-vector-into-iccs&#34;&gt;3.3 The optimal transfection time for the lentiviral vector into ICCs&lt;/h3&gt;
&lt;p&gt;To determine the optimal transfection time for the lentiviral vector containing the human SCL gene to ICCs, comparison of the green fluorescence in ICCs at different days was performed. The bladder ICC-like cells were transfected at the optimal MOI, and the transfection efficiencies were observed at 2 d, 3 d, and 5 d after transfection (&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_fig_003_w2aab3b7c51b1b6b1ab1b2b4b3Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Figure 3&lt;/a&gt;). After 3 days of transfection, the green fluorescence was the most obvious with the highest intensity, and after that the expression of GFP was weakened. After 3 d of lentiviral transfection, GFP expression in the ICCs was higher than in ICCs with 2d and 5d of transfection. Hence, the optimal transfection time for the lentiviral vector containing the human SCL gene in ICCs was 3 d.&lt;/p&gt;
&lt;p&gt;















&lt;figure  &gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img src=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/asset/graphic/j_biol-2020-0010_fig_003.jpg&#34; alt=&#34;Figure 3 The expression intensity of GFP in the lentivirus transfection group. The representative images at day 2, day 3, and day 5 are shown (200×).&#34; loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;h3 id=&#34;figure-3&#34;&gt;Figure 3&lt;/h3&gt;
&lt;p&gt;The expression intensity of GFP in the lentivirus transfection group. The representative images at day 2, day 3, and day 5 are shown (200×).&lt;/p&gt;
&lt;h3 id=&#34;34-the-expression-of-scl-mrna&#34;&gt;3.4 The expression of SCL mRNA&lt;/h3&gt;
&lt;p&gt;To determine whether the SCL gene was successfully introduced into ICCs, RT-PCR was performed to determine the expression of mRNA in each group. The amplification product of the lentiviral group was consistent with the target fragment in size, while there was no expression of the specific band in the normal control group and blank plasmid control group (&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_fig_004_w2aab3b7c51b1b6b1ab1b2b5b3Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Figure 4&lt;/a&gt;). This indicated that the SCL gene was successfully introduced into ICCs.&lt;/p&gt;
&lt;p&gt;















&lt;figure  &gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img src=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/asset/graphic/j_biol-2020-0010_fig_004.jpg&#34; alt=&#34;Figure 4 The expression of SCL mRNA analyzed by agarose gel electrophoresis. Lane 1: Normal control group; Lane 2: Blank plasmid control group; Lane M: Marker; Lane 4 and 5: Lentivirus transfection groups.&#34; loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;h3 id=&#34;figure-4&#34;&gt;Figure 4&lt;/h3&gt;
&lt;p&gt;The expression of SCL mRNA analyzed by agarose gel electrophoresis. Lane 1: Normal control group; Lane 2: Blank plasmid control group; Lane M: Marker; Lane 4 and 5: Lentivirus transfection groups.&lt;/p&gt;
&lt;h2 id=&#34;4-discussion&#34;&gt;4 Discussion&lt;/h2&gt;
&lt;p&gt;Studies [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_018_w2aab3b7c51b1b6b1ab2b2c18Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;18&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_019_w2aab3b7c51b1b6b1ab2b2c19Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;19&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_020_w2aab3b7c51b1b6b1ab2b2c20Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;20&lt;/a&gt;] have indicated that ICCs can control the spontaneous excitement and contraction of the detrusor. It has been shown that bladder ICCs can spontaneously generate action potentials using patch clamp [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_021_w2aab3b7c51b1b6b1ab2b2c21Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;21&lt;/a&gt;]. Blocking ICC action potentials significantly inhibits the contraction of detrusor cells [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_022_w2aab3b7c51b1b6b1ab2b2c22Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;22&lt;/a&gt;]. Some researchers believe that ICCs are capable of neural information conduction and may serve as the bladder pacemaker [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_022_w2aab3b7c51b1b6b1ab2b2c22Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;22&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_023_w2aab3b7c51b1b6b1ab2b2c23Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;23&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_024_w2aab3b7c51b1b6b1ab2b2c24Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;24&lt;/a&gt;]. However, ICC levels in the bladder detrusor of diabetic patients are low and show abnormal distribution or weakened spontaneous excitement, thus promoting the formation of DCP [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_025_w2aab3b7c51b1b6b1ab2b2c25Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;25&lt;/a&gt;]. Related studies [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_026_w2aab3b7c51b1b6b1ab2b2c26Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;26&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_027_w2aab3b7c51b1b6b1ab2b2c27Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;27&lt;/a&gt;] have found that the growth of ICCs is closely related to their specific tyrosine kinase receptor, c-kit. When the SCF/c-kit signaling pathway is successfully activated, the appearance and physiological characteristics of ICCs can be maintained [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_028_w2aab3b7c51b1b6b1ab2b2c28Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;28&lt;/a&gt;]. SCL is a transcription factor that can regulate the expression and function of c-kit, but it cannot bind to DNA directly [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_029_w2aab3b7c51b1b6b1ab2b2c29Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;29&lt;/a&gt;]. In the present study, the lentiviral vector containing the human SCL gene was constructed and transfected into &lt;em&gt;in vitro&lt;/em&gt; cultured ICCs. After transfection, the expression of SCL in ICCs was enhanced. These results may provide relevant information to further explore gene therapy for DCP.&lt;/p&gt;
&lt;p&gt;In this study, target cells were collected according to the adhesion time of bladder smooth muscle cells to bladder. After 24 h of incubation, ICCs were found to adhere to the culture plates, while bladder smooth muscle cells did not adhere. The non-adhered bladder muscle cells were filtered, and relatively pure bladder ICCs were obtained. Some characteristic spindle cells were observed under an inverted microscope. These cells had obvious convex branches on their sides, large nuclei, regular shapes, and were neatly adhered, while most of the non-adhered cells were oval, without projections on both poles and had overall flat shapes. The expression of the c-kit receptor was successful. Therefore, the cultured cells were confirmed to be bladder ICCs. The bladder ICCs obtained using this differential adherence method were of a relatively higher number and purer quality, but smooth muscle cells were still observed. This method is simple and time-cost effective and can provide enough cells for subsequent experiments.&lt;/p&gt;
&lt;p&gt;Lentivirus is a commonly used gene vector adapted from the human immunodeficiency virus -1. It retains biological activity but has inactivated toxicity, low immunogenicity, and good biosafety [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_030_w2aab3b7c51b1b6b1ab2b2c30Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;30&lt;/a&gt;]. Viral vectors can efficiently integrate target genes into host cells by gene recombination, unlikely to cause insertional mutagenesis [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_031_w2aab3b7c51b1b6b1ab2b2c31Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;31&lt;/a&gt;]. The target genes can express sustainably and stably [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_032_w2aab3b7c51b1b6b1ab2b2c32Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;32&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_033_w2aab3b7c51b1b6b1ab2b2c33Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;33&lt;/a&gt;]. Viral vectors have high transfection efficiencies for both dividing and non-dividing cells [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_034_w2aab3b7c51b1b6b1ab2b2c34Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;34&lt;/a&gt;]. Thus, they are an ideal tool for gene transfection both &lt;em&gt;in vitro&lt;/em&gt; and &lt;em&gt;in vivo&lt;/em&gt;. In this study, lentivirus was packaged by a three plasmid system which included one recombinant virus plasmid encoding lentivirus and its two secondary packaging element vector plasmids. The encoding plasmid and the helper plasmids have cis-trans complementary functions. In addition, the structures of the secondary packaging plasmids were constructed by pHelper1.0 and pHelper2.0 vectors. This method is relatively simple, the lentivirus recombination rate and yield are acceptable, and the expression of the target gene is high. During the experiment, the supernatant rich in lentiviral particles was collected and concentrated and purified repeatedly to obtain high-titer lentiviral stock solution. The expression of the target gene was determined after transfecting 293T cells, and the virus titer was determined by fluorescence. The results showed that the titer of the lentivirus was 5 × 108 TU /mL, which could meet the needs of most transfection experiments.&lt;/p&gt;
&lt;p&gt;Although the toxic genes of lentivirus have been excluded, its biological risk is not completely lost. Lentivirus is a “suicide” virus with certain cytotoxicity [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_035_w2aab3b7c51b1b6b1ab2b2c35Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;35&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_036_w2aab3b7c51b1b6b1ab2b2c36Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;36&lt;/a&gt;]. Studies have found that the transfection efficiency of lentivirus is closely related to its MOI, and high MOI can lead to some cell death [&lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_037_w2aab3b7c51b1b6b1ab2b2c37Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;37&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_038_w2aab3b7c51b1b6b1ab2b2c38Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;38&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_039_w2aab3b7c51b1b6b1ab2b2c39Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;39&lt;/a&gt;, &lt;a href=&#34;https://www.degruyter.com/document/doi/10.1515/biol-2020-0010/html#j_biol-2020-0010_ref_040_w2aab3b7c51b1b6b1ab2b2c40Aa&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;40&lt;/a&gt;]. Therefore, a proper MOI is important. In the current experiment, we found that the lentiviral transfection efficiency in ICCs was best at MOI = 10.0, and cell activity was good with no cell death. Considering the transfection efficiency and growth state of the cells, the optimal MOI value was determined to be 10.0. GFP is a bioluminescent protein that can steadily emit green fluorescence under the excitation of blue light and has no cytotoxicity. It is now widely used in cell biology and biopsy as a molecular marker or reporter gene. In this study, GFP was used as a marker gene of the lentivirus because of its stable and clear fluorescence. Under a fluorescence microscope, real-time and &lt;em&gt;in situ&lt;/em&gt; observation of living cells can be realized. Therefore, the transfection of the three plasmids into 293T cells to generate virus could be observed in real time, and accurate and intuitive results could be obtained. The ICCs were transfected with the lentivirus at the optimal MOI value and the expression of GFP was observed under a confocal microscope. The results showed that there was no GFP expressions in the normal control group and blank plasmid control group after 2 days of transfection. The GFP expression intensity in ICCs after 3 days of lentivirus transfection was higher than that after 2 days and 5 days, so the optimal transfection time for the lentivirus containing the human SCL gene into ICCs was 3 days. Comprehensively, for the transfection of lentivirus containing the human SCL gene into ICCs, the optimal MOI was 10.0, and the transfection efficiency, biological activity, and safety were highest after 72 hours of transfection. The results of RT-PCR indicated that the amplification product in the lentivirus transfection group had the same size as that of the target fragment, which was 1036 bp, while there was no expression of the specific band in the normal control group and blank plasmid control group. This suggested that the SCL gene was successfully introduced into ICCs.&lt;/p&gt;
&lt;p&gt;There are some limitations to the present study. &lt;em&gt;In vitro&lt;/em&gt; culture of cells is different from the body’s internal environment and might lose cell maintenance or auxiliary signals as well as interactions with other cells and proteins. &lt;em&gt;In vitro&lt;/em&gt; experiments cannot completely replicate the &lt;em&gt;in vivo&lt;/em&gt; situation, thus whether the transfection of DCP guinea pig bladder using a lentiviral vector containing the human SCL gene or other &lt;em&gt;in vivo&lt;/em&gt; experiments can obtain the same results needs further study.&lt;/p&gt;
&lt;p&gt;In conclusion, this study successfully constructed a recombinant lentiviral vector containing the human SCL gene by gene technology and molecular biological techniques. The titer of the lentivirus was 5 × 108 TU/ mL. &lt;em&gt;In vitro&lt;/em&gt; cultured ICCs were transfected with the lentiviral vector containing the human SCL gene, and SCL was successfully expressed in the ICCs. Our findings may provide a foundation for further &lt;em&gt;in vivo&lt;/em&gt; transfection studies using the SCL gene.&lt;/p&gt;
&lt;h1 id=&#34;acknowledgements&#34;&gt;Acknowledgements&lt;/h1&gt;
&lt;p&gt;This work was supported by National Natural Science Foundation [grant number 81360120].&lt;/p&gt;
&lt;h2 id=&#34;heading-1&#34;&gt;&lt;/h2&gt;
&lt;p&gt;&lt;strong&gt;Conflict of interest&lt;/strong&gt;: Authors state no conflict of interest.&lt;/p&gt;
&lt;h3 id=&#34;references&#34;&gt;References&lt;/h3&gt;
&lt;p&gt;[1] Liu G, Daneshgari F. Diabetic bladder dysfunction. Chin Med J (Engl) 2014; 127: 1357-1364 &lt;a href=&#34;https://scholar.google.com/scholar?q=Liu%20G,%20Daneshgari%20F.%20Diabetic%20bladder%20dysfunction.%20Chin%20Med%20J%20%28Engl%29%202014;%20127:%201357-1364%20Liu%20G%20Daneshgari%20F%20Diabetic%20bladder%20dysfunction%20Chin%20Med%20J%20%28Engl%29%202014%20127%201357%201364&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[2] Xu Y, Wang L, He J, Bi Y, Li M, Wang T et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013; 310: 948-959 &lt;a href=&#34;https://scholar.google.com/scholar?q=Xu%20Y,%20Wang%20L,%20He%20J,%20Bi%20Y,%20Li%20M,%20Wang%20T%20et%20al.%20Prevalence%20and%20control%20of%20diabetes%20in%20Chinese%20adults.%20JAMA%202013;%20310:%20948-959%20Xu%20Y%20Wang%20L%20He%20J%20Bi%20Y%20Li%20M%20Wang%20T%20Prevalence%20and%20control%20of%20diabetes%20in%20Chinese%20adults%20JAMA%202013%20310%20948%20959&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[3] Gomez CS, Kanagarajah P, Gousse AE. Bladder dysfunction in patients with diabetes. Current urology reports 2011; 12: 419-426 &lt;a href=&#34;https://scholar.google.com/scholar?q=Gomez%20CS,%20Kanagarajah%20P,%20Gousse%20AE.%20Bladder%20dysfunction%20in%20patients%20with%20diabetes.%20Current%20urology%20reports%202011;%2012:%20419-426%20Gomez%20CS%20Kanagarajah%20P%20Gousse%20AE%20Bladder%20dysfunction%20in%20patients%20with%20diabetes%20Current%20urology%20reports%202011%2012%20419%20426&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[4] Lin TL, Chen GD, Chen YC, Huang CN, Ng SC. Aging andrecurrent urinary tract infections are associated with bladder dysfunction in type 2 diabetes. Taiwan J Obstet Gynecol 2012; 51: 381-386 &lt;a href=&#34;https://scholar.google.com/scholar?q=Lin%20TL,%20Chen%20GD,%20Chen%20YC,%20Huang%20CN,%20Ng%20SC.%20Aging%20andrecurrent%20urinary%20tract%20infections%20are%20associated%20with%20bladder%20dysfunction%20in%20type%202%20diabetes.%20Taiwan%20J%20Obstet%20Gynecol%202012;%2051:%20381-386%20Lin%20TL%20Chen%20GD%20Chen%20YC%20Huang%20CN%20Ng%20SC%20Aging%20andrecurrent%20urinary%20tract%20infections%20are%20associated%20with%20bladder%20dysfunction%20in%20type%202%20diabetes%20Taiwan%20J%20Obstet%20Gynecol%202012%2051%20381%20386&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[5] Leiria LO, Monica FZ, Carvalho FD, Claudino MA, Franco-Penteado CF, Schenka A et al. Functional, morphological and molecular characterization of bladder dysfunction in streptozotocin-induced diabetic mice: evidence of a role for L-type voltage-operated Ca2+ channels. Br J Pharmacol 2011; 163: 1276-1288 &lt;a href=&#34;https://scholar.google.com/scholar?q=Leiria%20LO,%20Monica%20FZ,%20Carvalho%20FD,%20Claudino%20MA,%20Franco-Penteado%20CF,%20Schenka%20A%20et%20al.%20Functional,%20morphological%20and%20molecular%20characterization%20of%20bladder%20dysfunction%20in%20streptozotocin-induced%20diabetic%20mice:%20evidence%20of%20a%20role%20for%20L-type%20voltage-operated%20Ca2&amp;#43;%20channels.%20Br%20J%20Pharmacol%202011;%20163:%201276-1288%20Leiria%20LO%20Monica%20FZ%20Carvalho%20FD%20Claudino%20MA%20Franco-Penteado%20CF%20Schenka%20A%20Functional,%20morphological%20and%20molecular%20characterization%20of%20bladder%20dysfunction%20in%20streptozotocin-induced%20diabetic%20mice:%20evidence%20of%20a%20role%20for%20L-type%20voltage-operated%20Ca2&amp;#43;%20channels%20Br%20J%20Pharmacol%202011%20163%201276%201288&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[6] Li Y, Sun Y, Zhang Z, Feng X, Meng H, Li S et al. Cannabinoid receptors 1 and 2 are associated with bladder dysfunction in an experimental diabetic rat model. BJU Int 2013; 112: E143-150 &lt;a href=&#34;https://scholar.google.com/scholar?q=Li%20Y,%20Sun%20Y,%20Zhang%20Z,%20Feng%20X,%20Meng%20H,%20Li%20S%20et%20al.%20Cannabinoid%20receptors%201%20and%202%20are%20associated%20with%20bladder%20dysfunction%20in%20an%20experimental%20diabetic%20rat%20model.%20BJU%20Int%202013;%20112:%20E143-150%20Li%20Y%20Sun%20Y%20Zhang%20Z%20Feng%20X%20Meng%20H%20Li%20S%20Cannabinoid%20receptors%201%20and%202%20are%20associated%20with%20bladder%20dysfunction%20in%20an%20experimental%20diabetic%20rat%20model%20BJU%20Int%202013%20112%20E143%20150&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[7] Oberbach A, Jehmlich N, Schlichting N, Heinrich M, Lehmann S, Wirth H et al. Molecular fingerprint of high fat diet induced urinary bladder metabolic dysfunction in a rat model. PLoS One 2013; 8: e66636 &lt;a href=&#34;https://scholar.google.com/scholar?q=Oberbach%20A,%20Jehmlich%20N,%20Schlichting%20N,%20Heinrich%20M,%20Lehmann%20S,%20Wirth%20H%20et%20al.%20Molecular%20fingerprint%20of%20high%20fat%20diet%20induced%20urinary%20bladder%20metabolic%20dysfunction%20in%20a%20rat%20model.%20PLoS%20One%202013;%208:%20e66636%20Oberbach%20A%20Jehmlich%20N%20Schlichting%20N%20Heinrich%20M%20Lehmann%20S%20Wirth%20H%20Molecular%20fingerprint%20of%20high%20fat%20diet%20induced%20urinary%20bladder%20metabolic%20dysfunction%20in%20a%20rat%20model%20PLoS%20One%202013%208%20e66636&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[8] Briggs Boedtkjer D, Rumessen J, Baandrup U, Skov Mikkelsen M, Telinius N, Pilegaard H et al. Identification of interstitial Cajal-like cells in the human thoracic duct. Cells Tissues Organs 2013; 197: 145-158 &lt;a href=&#34;https://scholar.google.com/scholar?q=Briggs%20Boedtkjer%20D,%20Rumessen%20J,%20Baandrup%20U,%20Skov%20Mikkelsen%20M,%20Telinius%20N,%20Pilegaard%20H%20et%20al.%20Identification%20of%20interstitial%20Cajal-like%20cells%20in%20the%20human%20thoracic%20duct.%20Cells%20Tissues%20Organs%202013;%20197:%20145-158%20Briggs%20Boedtkjer%20D%20Rumessen%20J%20Baandrup%20U%20Skov%20Mikkelsen%20M%20Telinius%20N%20Pilegaard%20H%20Identification%20of%20interstitial%20Cajal-like%20cells%20in%20the%20human%20thoracic%20duct%20Cells%20Tissues%20Organs%202013%20197%20145%20158&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[9] Wang JP, Ding GF, Wang QZ. Interstitial cells of Cajal mediate excitatory sympathetic neurotransmission in guinea pig prostate. Cell Tissue Res 2013; 352: 479-486 &lt;a href=&#34;https://scholar.google.com/scholar?q=Wang%20JP,%20Ding%20GF,%20Wang%20QZ.%20Interstitial%20cells%20of%20Cajal%20mediate%20excitatory%20sympathetic%20neurotransmission%20in%20guinea%20pig%20prostate.%20Cell%20Tissue%20Res%202013;%20352:%20479-486%20Wang%20JP%20Ding%20GF%20Wang%20QZ%20Interstitial%20cells%20of%20Cajal%20mediate%20excitatory%20sympathetic%20neurotransmission%20in%20guinea%20pig%20prostate%20Cell%20Tissue%20Res%202013%20352%20479%20486&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[10] Yin Z, Yang J. Bladder interstitial cells and pathophysiology. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2014; 39: 644-648 &lt;a href=&#34;https://scholar.google.com/scholar?q=Yin%20Z,%20Yang%20J.%20Bladder%20interstitial%20cells%20and%20pathophysiology.%20Zhong%20Nan%20Da%20Xue%20Xue%20Bao%20Yi%20Xue%20Ban%202014;%2039:%20644-648%20Yin%20Z%20Yang%20J%20Bladder%20interstitial%20cells%20and%20pathophysiology%20Zhong%20Nan%20Da%20Xue%20Xue%20Bao%20Yi%20Xue%20Ban%202014%2039%20644%20648&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[11] Zhang YG, X.W. H, W. Z, Ma WQ, Wu YS, Wu Q et al. Excitability change and significance of interstitial cells of Cajal in rat bladder with detrusor hyperreflexia. Journal of Clinical Urology 2015: 168-171 &lt;a href=&#34;https://scholar.google.com/scholar?q=Zhang%20YG,%20X.W.%20H,%20W.%20Z,%20Ma%20WQ,%20Wu%20YS,%20Wu%20Q%20et%20al.%20Excitability%20change%20and%20significance%20of%20interstitial%20cells%20of%20Cajal%20in%20rat%20bladder%20with%20detrusor%20hyperreflexia.%20Journal%20of%20Clinical%20Urology%202015:%20168-171%20Zhang%20YG%20X.W.%20H,%20W.%20Z%20Ma%20WQ%20Wu%20YS%20Wu%20Q%20Excitability%20change%20and%20significance%20of%20interstitial%20cells%20of%20Cajal%20in%20rat%20bladder%20with%20detrusor%20hyperreflexia%20Journal%20of%20Clinical%20Urology%202015%20168-171&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[12] Wang L, Liang Y, Chen Q, et al. Identification and distribution of the interstitial cells of cajal in the abomasum of goats[J]. Cell Transplant, 2018, 27(2): 335-344. &lt;a href=&#34;https://scholar.google.com/scholar?q=Wang%20L,%20Liang%20Y,%20Chen%20Q,%20et%20al.%20Identification%20and%20distribution%20of%20the%20interstitial%20cells%20of%20cajal%20in%20the%20abomasum%20of%20goats[J].%20Cell%20Transplant,%202018,%2027%282%29:%20335-344.%20Wang%20L%20Liang%20Y%20Chen%20Q%20Identification%20and%20distribution%20of%20the%20interstitial%20cells%20of%20cajal%20in%20the%20abomasum%20of%20goats[J]%20Cell%20Transplant%202018%2027%202%20335%20344&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[13] Lang R J, Tonta M A, Zoltkowski B Z, et al. Pyeloureteric peristalsis: role of atypical smooth muscle cells and interstitial cells of Cajal-like cells as pacemakers.[J]. J Physiol, 2006, 576(3):695-705. &lt;a href=&#34;https://scholar.google.com/scholar?q=Lang%20R%20J,%20Tonta%20M%20A,%20Zoltkowski%20B%20Z,%20et%20al.%20Pyeloureteric%20peristalsis:%20role%20of%20atypical%20smooth%20muscle%20cells%20and%20interstitial%20cells%20of%20Cajal-like%20cells%20as%20pacemakers.[J].%20J%20Physiol,%202006,%20576%283%29:695-705.%20Lang%20R%20J%20Tonta%20M%20A%20Zoltkowski%20B%20Z%20Pyeloureteric%20peristalsis:%20role%20of%20atypical%20smooth%20muscle%20cells%20and%20interstitial%20cells%20of%20Cajal-like%20cells%20as%20pacemakers.[J]%20J%20Physiol%202006%20576%203%20695%20705&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[14] Wang QZ, Shi-Qi JI, Zhu GD, Yun-Fei LI, Cai ZQ, Ying-Long LI et al. The morphologic changes and significance of interstitial cells of Cajal-like cells in the bladder of diabetic guinea pig. Chinese Journal of Clinical &amp;amp; Experimental Pathology 2009; &lt;a href=&#34;https://scholar.google.com/scholar?q=Wang%20QZ,%20Shi-Qi%20JI,%20Zhu%20GD,%20Yun-Fei%20LI,%20Cai%20ZQ,%20Ying-Long%20LI%20et%20al.%20The%20morphologic%20changes%20and%20significance%20of%20interstitial%20cells%20of%20Cajal-like%20cells%20in%20the%20bladder%20of%20diabetic%20guinea%20pig.%20Chinese%20Journal%20of%20Clinical%20&amp;amp;%20Experimental%20Pathology%202009;%20Wang%20QZ%20Shi-Qi%20JI%20Zhu%20GD%20Yun-Fei%20LI%20Cai%20ZQ%20Ying-Long%20LI%20The%20morphologic%20changes%20and%20significance%20of%20interstitial%20cells%20of%20Cajal-like%20cells%20in%20the%20bladder%20of%20diabetic%20guinea%20pig%20Chinese%20Journal%20of%20Clinical%20&amp;amp;%20Experimental%20Pathology%202009&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[15] Liu YG, Wang QZ, Ding GF, Liu XJ, Zhou JM, Ying-Long LI et al. Effects of SCF on the expressions of c-kit mRNA and protein of interstitial cells of Cajal-like cells in the bladder of guinea pig in the high glucose environment. Chinese Journal of Clinical &amp;amp; Experimental Pathology 2011; 27: 282-285 &lt;a href=&#34;https://scholar.google.com/scholar?q=Liu%20YG,%20Wang%20QZ,%20Ding%20GF,%20Liu%20XJ,%20Zhou%20JM,%20Ying-Long%20LI%20et%20al.%20Effects%20of%20SCF%20on%20the%20expressions%20of%20c-kit%20mRNA%20and%20protein%20of%20interstitial%20cells%20of%20Cajal-like%20cells%20in%20the%20bladder%20of%20guinea%20pig%20in%20the%20high%20glucose%20environment.%20Chinese%20Journal%20of%20Clinical%20&amp;amp;%20Experimental%20Pathology%202011;%2027:%20282-285%20Liu%20YG%20Wang%20QZ%20Ding%20GF%20Liu%20XJ%20Zhou%20JM%20Ying-Long%20LI%20Effects%20of%20SCF%20on%20the%20expressions%20of%20c-kit%20mRNA%20and%20protein%20of%20interstitial%20cells%20of%20Cajal-like%20cells%20in%20the%20bladder%20of%20guinea%20pig%20in%20the%20high%20glucose%20environment%20Chinese%20Journal%20of%20Clinical%20&amp;amp;%20Experimental%20Pathology%202011%2027%20282%20285&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[16] Tan YY, Ji ZL, Zhao G, Jiang JR, Wang D, Wang JM. Decreased SCF/c-kit signaling pathway contributes to loss of interstitial cells of Cajal in gallstone disease. Int J Clin Exp Med 2014; 7: 4099-4106 &lt;a href=&#34;https://scholar.google.com/scholar?q=Tan%20YY,%20Ji%20ZL,%20Zhao%20G,%20Jiang%20JR,%20Wang%20D,%20Wang%20JM.%20Decreased%20SCF/c-kit%20signaling%20pathway%20contributes%20to%20loss%20of%20interstitial%20cells%20of%20Cajal%20in%20gallstone%20disease.%20Int%20J%20Clin%20Exp%20Med%202014;%207:%204099-4106%20Tan%20YY%20Ji%20ZL%20Zhao%20G%20Jiang%20JR%20Wang%20D%20Wang%20JM%20Decreased%20SCF/c-kit%20signaling%20pathway%20contributes%20to%20loss%20of%20interstitial%20cells%20of%20Cajal%20in%20gallstone%20disease%20Int%20J%20Clin%20Exp%20Med%202014%207%204099%204106&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[17] Kart Y, Karakus OZ, Ates O, Hakguder G, Olguner M, Akgur FM. Altered expression of interstitial cells of Cajal in primary obstructive megaureter. J Pediatr Urol 2013; 9: 1028-1031 &lt;a href=&#34;https://scholar.google.com/scholar?q=Kart%20Y,%20Karakus%20OZ,%20Ates%20O,%20Hakguder%20G,%20Olguner%20M,%20Akgur%20FM.%20Altered%20expression%20of%20interstitial%20cells%20of%20Cajal%20in%20primary%20obstructive%20megaureter.%20J%20Pediatr%20Urol%202013;%209:%201028-1031%20Kart%20Y%20Karakus%20OZ%20Ates%20O%20Hakguder%20G%20Olguner%20M%20Akgur%20FM%20Altered%20expression%20of%20interstitial%20cells%20of%20Cajal%20in%20primary%20obstructive%20megaureter%20J%20Pediatr%20Urol%202013%209%201028%201031&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[18] Feng J, Liu Y, Gao J, Zhong Y, Shu Y, Meng M et al. Effect of exogenous stem cell factor on numbers of interstitial cells of Cajal and detrusor contraction in rats with underactive bladder. Journal of Third Military Medical University 2016; &lt;a href=&#34;https://scholar.google.com/scholar?q=Feng%20J,%20Liu%20Y,%20Gao%20J,%20Zhong%20Y,%20Shu%20Y,%20Meng%20M%20et%20al.%20Effect%20of%20exogenous%20stem%20cell%20factor%20on%20numbers%20of%20interstitial%20cells%20of%20Cajal%20and%20detrusor%20contraction%20in%20rats%20with%20underactive%20bladder.%20Journal%20of%20Third%20Military%20Medical%20University%202016;%20Feng%20J%20Liu%20Y%20Gao%20J%20Zhong%20Y%20Shu%20Y%20Meng%20M%20Effect%20of%20exogenous%20stem%20cell%20factor%20on%20numbers%20of%20interstitial%20cells%20of%20Cajal%20and%20detrusor%20contraction%20in%20rats%20with%20underactive%20bladder%20Journal%20of%20Third%20Military%20Medical%20University%202016&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[19] Juszczak K, Maciukiewicz P, Drewa T, Thor PJ. Cajal–like interstitial cells as a novel target in detrusor overactivity treatment: true or myth? Central European Journal of Urology 2014; 66: 413 &lt;a href=&#34;https://scholar.google.com/scholar?q=Juszczak%20K,%20Maciukiewicz%20P,%20Drewa%20T,%20Thor%20PJ.%20Cajal%E2%80%93like%20interstitial%20cells%20as%20a%20novel%20target%20in%20detrusor%20overactivity%20treatment:%20true%20or%20myth?%20Central%20European%20Journal%20of%20Urology%202014;%2066:%20413%20Juszczak%20K%20Maciukiewicz%20P%20Drewa%20T%20Thor%20PJ%20Cajal%E2%80%93like%20interstitial%20cells%20as%20a%20novel%20target%20in%20detrusor%20overactivity%20treatment:%20true%20or%20myth?%20Central%20European%20Journal%20of%20Urology%202014%2066%20413&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[20] Kim SO, Song SH, Ahn KY, Kwon DD. Distribution of interstitial cells of cajal in menopausal rat urinary bladder showing detrusor overactivity. Int Neurourol J 2010; 14: 48-53 &lt;a href=&#34;https://scholar.google.com/scholar?q=Kim%20SO,%20Song%20SH,%20Ahn%20KY,%20Kwon%20DD.%20Distribution%20of%20interstitial%20cells%20of%20cajal%20in%20menopausal%20rat%20urinary%20bladder%20showing%20detrusor%20overactivity.%20Int%20Neurourol%20J%202010;%2014:%2048-53%20Kim%20SO%20Song%20SH%20Ahn%20KY%20Kwon%20DD%20Distribution%20of%20interstitial%20cells%20of%20cajal%20in%20menopausal%20rat%20urinary%20bladder%20showing%20detrusor%20overactivity%20Int%20Neurourol%20J%202010%2014%2048%2053&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[21] Kim BJ, Kim HW, Lee GS, Choi S, Jun JY, So I et al. Poncirus trifoliate fruit modulates pacemaker activity in interstitial cells of Cajal from the murine small intestine. J Ethnopharmacol 2013; 149: 668-675 &lt;a href=&#34;https://scholar.google.com/scholar?q=Kim%20BJ,%20Kim%20HW,%20Lee%20GS,%20Choi%20S,%20Jun%20JY,%20So%20I%20et%20al.%20Poncirus%20trifoliate%20fruit%20modulates%20pacemaker%20activity%20in%20interstitial%20cells%20of%20Cajal%20from%20the%20murine%20small%20intestine.%20J%20Ethnopharmacol%202013;%20149:%20668-675%20Kim%20BJ%20Kim%20HW%20Lee%20GS%20Choi%20S%20Jun%20JY%20So%20I%20Poncirus%20trifoliate%20fruit%20modulates%20pacemaker%20activity%20in%20interstitial%20cells%20of%20Cajal%20from%20the%20murine%20small%20intestine%20J%20Ethnopharmacol%202013%20149%20668%20675&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[22] Zuo DC, Choi S, Shahi PK, Kim MY, Park CG, Kim YD et al. Inhibition of pacemaker activity in interstitial cells of Cajal by LPS via NF-kappaB and MAP kinase. World J Gastroenterol 2013; 19: 1210-1218 &lt;a href=&#34;https://scholar.google.com/scholar?q=Zuo%20DC,%20Choi%20S,%20Shahi%20PK,%20Kim%20MY,%20Park%20CG,%20Kim%20YD%20et%20al.%20Inhibition%20of%20pacemaker%20activity%20in%20interstitial%20cells%20of%20Cajal%20by%20LPS%20via%20NF-kappaB%20and%20MAP%20kinase.%20World%20J%20Gastroenterol%202013;%2019:%201210-1218%20Zuo%20DC%20Choi%20S%20Shahi%20PK%20Kim%20MY%20Park%20CG%20Kim%20YD%20Inhibition%20of%20pacemaker%20activity%20in%20interstitial%20cells%20of%20Cajal%20by%20LPS%20via%20NF-kappaB%20and%20MAP%20kinase%20World%20J%20Gastroenterol%202013%2019%201210%201218&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[23] Han S, Kim JS, Jung BK, Han SE, Nam JH, Kwon YK et al. Effects of ginsenoside on pacemaker potentials of cultured interstitial cells of Cajal clusters from the small intestine of mice. Mol Cells 2012; 33: 243-249 &lt;a href=&#34;https://scholar.google.com/scholar?q=Han%20S,%20Kim%20JS,%20Jung%20BK,%20Han%20SE,%20Nam%20JH,%20Kwon%20YK%20et%20al.%20Effects%20of%20ginsenoside%20on%20pacemaker%20potentials%20of%20cultured%20interstitial%20cells%20of%20Cajal%20clusters%20from%20the%20small%20intestine%20of%20mice.%20Mol%20Cells%202012;%2033:%20243-249%20Han%20S%20Kim%20JS%20Jung%20BK%20Han%20SE%20Nam%20JH%20Kwon%20YK%20Effects%20of%20ginsenoside%20on%20pacemaker%20potentials%20of%20cultured%20interstitial%20cells%20of%20Cajal%20clusters%20from%20the%20small%20intestine%20of%20mice%20Mol%20Cells%202012%2033%20243%20249&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[24] Lee J, Kim YD, Park CG, Kim MY, Chang IY, Zuo DC et al. Neurotensin modulates pacemaker activity in interstitial cells of Cajal from the mouse small intestine. Mol Cells 2012; 33: 509-516 &lt;a href=&#34;https://scholar.google.com/scholar?q=Lee%20J,%20Kim%20YD,%20Park%20CG,%20Kim%20MY,%20Chang%20IY,%20Zuo%20DC%20et%20al.%20Neurotensin%20modulates%20pacemaker%20activity%20in%20interstitial%20cells%20of%20Cajal%20from%20the%20mouse%20small%20intestine.%20Mol%20Cells%202012;%2033:%20509-516%20Lee%20J%20Kim%20YD%20Park%20CG%20Kim%20MY%20Chang%20IY%20Zuo%20DC%20Neurotensin%20modulates%20pacemaker%20activity%20in%20interstitial%20cells%20of%20Cajal%20from%20the%20mouse%20small%20intestine%20Mol%20Cells%202012%2033%20509%20516&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[25] Sanders KM, Koh SD, Ward SM. Interstitial cells of cajal as pacemakers in the gastrointestinal tract. Annu Rev Physiol 2006; 68: 307-343 &lt;a href=&#34;https://scholar.google.com/scholar?q=Sanders%20KM,%20Koh%20SD,%20Ward%20SM.%20Interstitial%20cells%20of%20cajal%20as%20pacemakers%20in%20the%20gastrointestinal%20tract.%20Annu%20Rev%20Physiol%202006;%2068:%20307-343%20Sanders%20KM%20Koh%20SD%20Ward%20SM%20Interstitial%20cells%20of%20cajal%20as%20pacemakers%20in%20the%20gastrointestinal%20tract%20Annu%20Rev%20Physiol%202006%2068%20307%20343&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[26] Sung R, Kim YC, Yun HY, Choi W, Kim HS, Kim H et al. Interstitial cells of Cajal (ICC)-like-c-Kit positive cells are involved in gastritis and carcinogenesis in human stomach. Oncol Rep 2011; 26: 33-42 &lt;a href=&#34;https://scholar.google.com/scholar?q=Sung%20R,%20Kim%20YC,%20Yun%20HY,%20Choi%20W,%20Kim%20HS,%20Kim%20H%20et%20al.%20Interstitial%20cells%20of%20Cajal%20%28ICC%29-like-c-Kit%20positive%20cells%20are%20involved%20in%20gastritis%20and%20carcinogenesis%20in%20human%20stomach.%20Oncol%20Rep%202011;%2026:%2033-42%20Sung%20R%20Kim%20YC%20Yun%20HY%20Choi%20W%20Kim%20HS%20Kim%20H%20Interstitial%20cells%20of%20Cajal%20%28ICC%29-like-c-Kit%20positive%20cells%20are%20involved%20in%20gastritis%20and%20carcinogenesis%20in%20human%20stomach%20Oncol%20Rep%202011%2026%2033%2042&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[27] Wang XY, Chen JH, Li K, Zhu YF, Wright GW, Huizinga JD. Discrepancies between c-Kit positive and Ano1 positive ICC-SMP in the W/Wv and wild-type mouse colon; relationships with motor patterns and calcium transients. Neurogastroenterol Motil 2015; 26: 1298-1310 &lt;a href=&#34;https://scholar.google.com/scholar?q=Wang%20XY,%20Chen%20JH,%20Li%20K,%20Zhu%20YF,%20Wright%20GW,%20Huizinga%20JD.%20Discrepancies%20between%20c-Kit%20positive%20and%20Ano1%20positive%20ICC-SMP%20in%20the%20W/Wv%20and%20wild-type%20mouse%20colon;%20relationships%20with%20motor%20patterns%20and%20calcium%20transients.%20Neurogastroenterol%20Motil%202015;%2026:%201298-1310%20Wang%20XY%20Chen%20JH%20Li%20K%20Zhu%20YF%20Wright%20GW%20Huizinga%20JD%20Discrepancies%20between%20c-Kit%20positive%20and%20Ano1%20positive%20ICC-SMP%20in%20the%20W/Wv%20and%20wild-type%20mouse%20colon;%20relationships%20with%20motor%20patterns%20and%20calcium%20transients%20Neurogastroenterol%20Motil%202015%2026%201298%201310&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[28] Ward SM, Sanders KM. Physiology and pathophysiology of the interstitial cell of Cajal: from bench to bedside. I. Functional development and plasticity of interstitial cells of Cajal networks. Am J Physiol Gastrointest Liver Physiol 2001; 281: G602-611 &lt;a href=&#34;https://scholar.google.com/scholar?q=Ward%20SM,%20Sanders%20KM.%20Physiology%20and%20pathophysiology%20of%20the%20interstitial%20cell%20of%20Cajal:%20from%20bench%20to%20bedside.%20I.%20Functional%20development%20and%20plasticity%20of%20interstitial%20cells%20of%20Cajal%20networks.%20Am%20J%20Physiol%20Gastrointest%20Liver%20Physiol%202001;%20281:%20G602-611%20Ward%20SM%20Sanders%20KM%20Physiology%20and%20pathophysiology%20of%20the%20interstitial%20cell%20of%20Cajal:%20from%20bench%20to%20bedside.%20I.%20Functional%20development%20and%20plasticity%20of%20interstitial%20cells%20of%20Cajal%20networks%20Am%20J%20Physiol%20Gastrointest%20Liver%20Physiol%202001%20281%20G602%20611&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[29] Li F, Zhang L, Li C, Ni B, Wu Y, Huang Y et al. Adenovirus-mediated stem cell leukemia gene transfer induces rescue of interstitial cells of Cajal in ICC-loss mice. Int J Colorectal Dis 2010; 25: 557-566 &lt;a href=&#34;https://scholar.google.com/scholar?q=Li%20F,%20Zhang%20L,%20Li%20C,%20Ni%20B,%20Wu%20Y,%20Huang%20Y%20et%20al.%20Adenovirus-mediated%20stem%20cell%20leukemia%20gene%20transfer%20induces%20rescue%20of%20interstitial%20cells%20of%20Cajal%20in%20ICC-loss%20mice.%20Int%20J%20Colorectal%20Dis%202010;%2025:%20557-566%20Li%20F%20Zhang%20L%20Li%20C%20Ni%20B%20Wu%20Y%20Huang%20Y%20Adenovirus-mediated%20stem%20cell%20leukemia%20gene%20transfer%20induces%20rescue%20of%20interstitial%20cells%20of%20Cajal%20in%20ICC-loss%20mice%20Int%20J%20Colorectal%20Dis%202010%2025%20557%20566&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[30] Rusu MC, Pop F, Hostiuc S, Curca GC, Streinu-Cercel A. Extrahepatic and intrahepatic human portal interstitial Cajal cells. Anat Rec (Hoboken) 2011; 294: 1382-1392 &lt;a href=&#34;https://scholar.google.com/scholar?q=Rusu%20MC,%20Pop%20F,%20Hostiuc%20S,%20Curca%20GC,%20Streinu-Cercel%20A.%20Extrahepatic%20and%20intrahepatic%20human%20portal%20interstitial%20Cajal%20cells.%20Anat%20Rec%20%28Hoboken%29%202011;%20294:%201382-1392%20Rusu%20MC%20Pop%20F%20Hostiuc%20S%20Curca%20GC%20Streinu-Cercel%20A%20Extrahepatic%20and%20intrahepatic%20human%20portal%20interstitial%20Cajal%20cells%20Anat%20Rec%20%28Hoboken%29%202011%20294%201382%201392&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[31] Ranzani M, Annunziato S, Calabria A, Brasca S, Benedicenti F, Gallina P et al. Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies. Mol Ther 2014; 22: 2056-2068 &lt;a href=&#34;https://scholar.google.com/scholar?q=Ranzani%20M,%20Annunziato%20S,%20Calabria%20A,%20Brasca%20S,%20Benedicenti%20F,%20Gallina%20P%20et%20al.%20Lentiviral%20vector-based%20insertional%20mutagenesis%20identifies%20genes%20involved%20in%20the%20resistance%20to%20targeted%20anticancer%20therapies.%20Mol%20Ther%202014;%2022:%202056-2068%20Ranzani%20M%20Annunziato%20S%20Calabria%20A%20Brasca%20S%20Benedicenti%20F%20Gallina%20P%20Lentiviral%20vector-based%20insertional%20mutagenesis%20identifies%20genes%20involved%20in%20the%20resistance%20to%20targeted%20anticancer%20therapies%20Mol%20Ther%202014%2022%202056%202068&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[32] Xie B, Yu G, Ling S, Ma Z, Bai J. Establishment of MDCK cell lines which stably express FRT-LacZ gene by lentiviral system. Biotechnology 2016; &lt;a href=&#34;https://scholar.google.com/scholar?q=Xie%20B,%20Yu%20G,%20Ling%20S,%20Ma%20Z,%20Bai%20J.%20Establishment%20of%20MDCK%20cell%20lines%20which%20stably%20express%20FRT-LacZ%20gene%20by%20lentiviral%20system.%20Biotechnology%202016;%20Xie%20B%20Yu%20G%20Ling%20S%20Ma%20Z%20Bai%20J%20Establishment%20of%20MDCK%20cell%20lines%20which%20stably%20express%20FRT-LacZ%20gene%20by%20lentiviral%20system%20Biotechnology%202016&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[33] Zhang J, Wang D, Hu N, Wang Q, Yu S, Wang J. The construction and proliferative effects of a lentiviral vector capable of stably overexpressing SPINK1 gene in human pancreatic cancer AsPC-1 cell line. Tumour Biol 2016; 37: 5847-5855 &lt;a href=&#34;https://scholar.google.com/scholar?q=Zhang%20J,%20Wang%20D,%20Hu%20N,%20Wang%20Q,%20Yu%20S,%20Wang%20J.%20The%20construction%20and%20proliferative%20effects%20of%20a%20lentiviral%20vector%20capable%20of%20stably%20overexpressing%20SPINK1%20gene%20in%20human%20pancreatic%20cancer%20AsPC-1%20cell%20line.%20Tumour%20Biol%202016;%2037:%205847-5855%20Zhang%20J%20Wang%20D%20Hu%20N%20Wang%20Q%20Yu%20S%20Wang%20J%20The%20construction%20and%20proliferative%20effects%20of%20a%20lentiviral%20vector%20capable%20of%20stably%20overexpressing%20SPINK1%20gene%20in%20human%20pancreatic%20cancer%20AsPC-1%20cell%20line%20Tumour%20Biol%202016%2037%205847%205855&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[34] Pelascini LP, Janssen JM, Goncalves MA. Histone deacetylase inhibition activates transgene expression from integration-defective lentiviral vectors in dividing and non-dividing cells. Hum Gene Ther 2013; 24: 78-96 &lt;a href=&#34;https://scholar.google.com/scholar?q=Pelascini%20LP,%20Janssen%20JM,%20Goncalves%20MA.%20Histone%20deacetylase%20inhibition%20activates%20transgene%20expression%20from%20integration-defective%20lentiviral%20vectors%20in%20dividing%20and%20non-dividing%20cells.%20Hum%20Gene%20Ther%202013;%2024:%2078-96%20Pelascini%20LP%20Janssen%20JM%20Goncalves%20MA%20Histone%20deacetylase%20inhibition%20activates%20transgene%20expression%20from%20integration-defective%20lentiviral%20vectors%20in%20dividing%20and%20non-dividing%20cells%20Hum%20Gene%20Ther%202013%2024%2078%2096&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[35] Hossain JA, Ystaas LR, Mrdalj J, Välk K, Riecken K, Fehse B et al. Lentiviral HSV‐Tk.007‐mediated suicide gene therapy is not toxic for normal brain cells. J Gene Med 2016; 18: 234-243 &lt;a href=&#34;https://scholar.google.com/scholar?q=Hossain%20JA,%20Ystaas%20LR,%20Mrdalj%20J,%20V%C3%A4lk%20K,%20Riecken%20K,%20Fehse%20B%20et%20al.%20Lentiviral%20HSV%E2%80%90Tk.007%E2%80%90mediated%20suicide%20gene%20therapy%20is%20not%20toxic%20for%20normal%20brain%20cells.%20J%20Gene%20Med%202016;%2018:%20234-243%20Hossain%20JA%20Ystaas%20LR%20Mrdalj%20J%20V%C3%A4lk%20K%20Riecken%20K%20Fehse%20B%20Lentiviral%20HSV%E2%80%90Tk.007%E2%80%90mediated%20suicide%20gene%20therapy%20is%20not%20toxic%20for%20normal%20brain%20cells%20J%20Gene%20Med%202016%2018%20234%20243&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[36] Mohammadi Z, Shariati L, Khanahmad H, Kolahdouz M, Kianpoor F, Ghanbari JA et al. A Lentiviral Vector Expressing Desired Gene Only in Transduced Cells: An Approach for Suicide Gene Therapy. Mol Biotechnol 2015; 57: 793-800 &lt;a href=&#34;https://scholar.google.com/scholar?q=Mohammadi%20Z,%20Shariati%20L,%20Khanahmad%20H,%20Kolahdouz%20M,%20Kianpoor%20F,%20Ghanbari%20JA%20et%20al.%20A%20Lentiviral%20Vector%20Expressing%20Desired%20Gene%20Only%20in%20Transduced%20Cells:%20An%20Approach%20for%20Suicide%20Gene%20Therapy.%20Mol%20Biotechnol%202015;%2057:%20793-800%20Mohammadi%20Z%20Shariati%20L%20Khanahmad%20H%20Kolahdouz%20M%20Kianpoor%20F%20Ghanbari%20JA%20A%20Lentiviral%20Vector%20Expressing%20Desired%20Gene%20Only%20in%20Transduced%20Cells:%20An%20Approach%20for%20Suicide%20Gene%20Therapy%20Mol%20Biotechnol%202015%2057%20793%20800&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[37] Hu Y, Zhang Q, Zhang L, Tang XX, He HY. Basic fibroblast growth factor lentiviral vector-transfected sheep bone marrow mesenchymal stem cells and non-specific osteogenic gene expression. Mol Med Rep 2015; 12: 267-272 &lt;a href=&#34;https://scholar.google.com/scholar?q=Hu%20Y,%20Zhang%20Q,%20Zhang%20L,%20Tang%20XX,%20He%20HY.%20Basic%20fibroblast%20growth%20factor%20lentiviral%20vector-transfected%20sheep%20bone%20marrow%20mesenchymal%20stem%20cells%20and%20non-specific%20osteogenic%20gene%20expression.%20Mol%20Med%20Rep%202015;%2012:%20267-272%20Hu%20Y%20Zhang%20Q%20Zhang%20L%20Tang%20XX%20He%20HY%20Basic%20fibroblast%20growth%20factor%20lentiviral%20vector-transfected%20sheep%20bone%20marrow%20mesenchymal%20stem%20cells%20and%20non-specific%20osteogenic%20gene%20expression%20Mol%20Med%20Rep%202015%2012%20267%20272&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[38] Huang GH, Yang XT, Chen K, Xing J, Zhu L, Hong-Jiang LI et al. Construction of lentiviral vector with over-expression of Porf-2 gene and transfection of neural cells. Journal of Shanghai Jiaotong University 2015; 87: 480 &lt;a href=&#34;https://scholar.google.com/scholar?q=Huang%20GH,%20Yang%20XT,%20Chen%20K,%20Xing%20J,%20Zhu%20L,%20Hong-Jiang%20LI%20et%20al.%20Construction%20of%20lentiviral%20vector%20with%20over-expression%20of%20Porf-2%20gene%20and%20transfection%20of%20neural%20cells.%20Journal%20of%20Shanghai%20Jiaotong%20University%202015;%2087:%20480%20Huang%20GH%20Yang%20XT%20Chen%20K%20Xing%20J%20Zhu%20L%20Hong-Jiang%20LI%20Construction%20of%20lentiviral%20vector%20with%20over-expression%20of%20Porf-2%20gene%20and%20transfection%20of%20neural%20cells%20Journal%20of%20Shanghai%20Jiaotong%20University%202015%2087%20480&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[39] Jiao ZZ, Xue WJ, Tian XH, Li Y, Zheng J. Construction of VEGF165 lentivirus vectors and expression in adipose tissue-derived stem cells after transfection. Chin Pharm J 2016; &lt;a href=&#34;https://scholar.google.com/scholar?q=Jiao%20ZZ,%20Xue%20WJ,%20Tian%20XH,%20Li%20Y,%20Zheng%20J.%20Construction%20of%20VEGF165%20lentivirus%20vectors%20and%20expression%20in%20adipose%20tissue-derived%20stem%20cells%20after%20transfection.%20Chin%20Pharm%20J%202016;%20Jiao%20ZZ%20Xue%20WJ%20Tian%20XH%20Li%20Y%20Zheng%20J%20Construction%20of%20VEGF165%20lentivirus%20vectors%20and%20expression%20in%20adipose%20tissue-derived%20stem%20cells%20after%20transfection%20Chin%20Pharm%20J%202016&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;[40] Wang X, Mani P, Sarkar DP, Roychowdhury N, Roychowdhury J. Ex vivo gene transfer into hepatocytes. Methods Mol Biol 2009; 481: 117 &lt;a href=&#34;https://scholar.google.com/scholar?q=Wang%20X,%20Mani%20P,%20Sarkar%20DP,%20Roychowdhury%20N,%20Roychowdhury%20J.%20Ex%20vivo%20gene%20transfer%20into%20hepatocytes.%20Methods%20Mol%20Biol%202009;%20481:%20117%20Wang%20X%20Mani%20P%20Sarkar%20DP%20Roychowdhury%20N%20Roychowdhury%20J%20Ex%20vivo%20gene%20transfer%20into%20hepatocytes%20Methods%20Mol%20Biol%202009%20481%20117&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Search in Google Scholar&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Received:&lt;/strong&gt; 2018-08-29&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accepted:&lt;/strong&gt; 2019-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Published Online:&lt;/strong&gt; 2020-03-25&lt;/p&gt;
&lt;p&gt;© 2020 Biao Qian et al. published by De Gruyter&lt;/p&gt;
&lt;p&gt;This work is licensed under the Creative Commons Attribution 4.0 International License.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
